






























The Dissertation Committee for Shannon Laine Zandy certifies that this is the 




Effects of opioid antagonism on operant ethanol self-administration in 














Rueben A. Gonzales, Supervisor 
R. Adron Harris 
Michela Marinelli 
Hitoshi Morikawa 




Effects of opioid antagonism on operant ethanol self-administration in 








Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 












I would like to acknowledge my dissertation committee members for their service, 
time, and support of my doctoral candidacy: Rueben A. Gonzales, Ph.D., R. Adron 
Harris, Ph.D., Micky Marinelli, Ph.D., Hitoshi Morikawa, Ph.D., and Richard A. 
Morrisett, Ph.D. 
I would like to acknowledge my scientific mentors: Joanna Peris, Ph.D., for 
introducing me to research and sending ongoing encouragement; Doug Matthews, Ph.D., 
for furthering my training and always providing valuable perspective; and finally, Rueben 
A. Gonzales, Ph.D., my graduate supervisor, for all of his support and guidance over the 
years.  
I would like to acknowledge my colleagues for their scientific discussions, 
friendship and enduring patience: Ashley Vena, Roberto Cofresi, James Reno, Ph.D., 
Christy Schier, Ph.D., Jennifer Carrillo, Ph.D., Esther Maier, Ph.D., Regina Mangieri, 
Ph.D., Armando Salinas, Ph.D., James Doherty, Ph.D., Neha Thakore, Pharm.D., John 
Valenta, Ph.D. 
Finally, I would like to acknowledge my family and friends, especially my 





Effects of opioid antagonism on operant ethanol self-administration in 
adolescence and characterization of extracellular GABA in the ventral 
tegmental area 
 
Shannon Laine Zandy, Ph.D. 
The University of Texas at Austin, 2016 
 
Supervisor:  Rueben A. Gonzales 
 
 The endogenous opioid peptide system is hypothesized to be involved in ethanol 
self-administration and relapse behaviors. Naltrexone, a nonselective opioid antagonist, is 
an approved medication for alcohol use disorder which has been shown to decrease 
drinking in adult animal models and select clinical populations, but little is known about 
the efficacy of naltrexone in animal models that begin drinking ethanol in adolescence. 
Therefore, we investigated the effects of systemic naltrexone administration in an 
adolescent rat model of operant ethanol self-administration. We found that naltrexone 
significantly reduced ethanol intake and motivation to obtain ethanol in adolescent and 
adult rats. Following a period of abstinence, naltrexone also significantly reduced 
“relapse” to alcohol seeking in both age groups. These results extend findings that 
naltrexone is effective at reducing ethanol intake to an adolescent animal model and 
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support opioid antagonism as a treatment strategy for decreasing problem drinking in late 
adolescents and young adults. 
 One potential mechanism underlying the effects of opioid receptor blockade on 
ethanol self-administration implicates γ-aminobutyric acid (GABA) neurons within the 
ventral tegmental area (VTA). Inhibitory signaling in the VTA is involved in the 
mechanism of action of many drugs of abuse yet there are few studies measuring 
extracellular GABA concentration in this region. Therefore, the remaining experiments 
focused on developing methods to quantify extracellular GABA in the VTA.  
 We first describe a novel, sensitive fluorescence method to quantify GABA 
concentration using high performance liquid chromatography (HPLC) of an o-
phthalaldehyde/sulfite derivative, previously reported to produce low fluorescence not 
suitable for in vivo microdialysis applications. Next, we used quantitative microdialysis 
under transient conditions to characterize basal extracellular GABA concentration and the 
influence of uptake mechanisms in the VTA. Our results show that inhibition of GABA 
uptake significantly increased extracellular GABA concentration and reduced in vivo 
extraction fraction of the probe. Reduced in vivo extraction fraction caused significant 
underestimation of the increase in extracellular GABA by conventional microdialysis. 
Together, these results establish the foundation for future studies to investigate the 
regulation of extracellular GABA concentration and uptake mechanisms in the VTA in 
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Chapter 1: Background 
 
ALCOHOL USE  
Overview 
 Alcohol abuse and dependence are a widespread public health issue within the 
United States. Alcohol is the most commonly used drug with 140 million people 
reporting current use (SAMHSA 2015), yet we still do not fully understand the 
neurobiological mechanisms underlying alcohol consumption and the transition to 
problematic drinking or dependence. However, the prevalence of alcohol abuse is an 
ongoing problem, as nearly 15% of individuals meet diagnostic criteria for alcohol abuse 
or dependence by 18 years of age (Swendsen et al. 2012). In addition the negative 
consequences on public health, alcohol misuse cost the United States $249 billion in 
2010, and 77% of those costs were due to binge drinking (Sacks et al. 2015). 
Adolescent alcohol use 
 Alcohol is the most commonly abused substance in adolescence, and 
approximately 16% of individuals age 12 to 20 were classified as binge drinkers in the 
United States (SAMHSA 2015; Witt 2010). Additionally, over 6% of adolescents meet 
criteria for alcohol dependence (Swendsen et al. 2012). Adolescence is a period of 
profound neurobiological and behavioral development, which can result in an increased 
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propensity to abuse alcohol (Casey and Jones 2010; Spear 2000). Indeed, a strong 
predictor of progression to alcohol-related problems is age of first use. Individuals who 
start drinking alcohol before the age of 14 were reported four times more likely to 
develop alcohol dependence later in life (DeWit et al. 2000; Grant and Dawson 1997). 
Additionally, individuals who begin drinking earlier in life are more likely to progress to 
alcohol dependence within the first ten years of drinking (Hingson et al. 2006). Overall, 
the consequences of alcohol use in adolescence have a clear and significant impact on 
future problems with alcohol. 
Current treatment strategies 
 Despite the prevalence of alcohol dependence, there are only four approved 
pharmacological treatment options: acamprosate, disulfiram, oral naltrexone and long-
acting injectable naltrexone. Disulfiram (Antabuse) inhibits acetaldehyde dehydrogenase 
and causes an aversive reaction when drinking alcohol. In contrast, acamprosate 
(Campral) and naltrexone (Revia, Vivitrol) are thought to be effective by reducing 
alcohol cravings (Litten et al. 2005). Acamprosate has been shown effective at reducing 
relapse to alcohol drinking (Rosner et al. 2010). Originally thought be a γ-aminobutyric 
acid (GABA) analogue, it may actually exert its effect via calcium (Spanagel et al. 2014). 
Naltrexone (Revia, Vivitrol), an opioid receptor antagonist, has been shown to reduce 
alcohol intake and risk of relapse in some (O’Malley et al. 1992; Sinclair 2001; 
Volpicelli et al. 1992), but not all clinical studies (Krystal et al. 2001). There is an 
ongoing need for development of new treatments, however only 20% of people who 
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abuse alcohol were reported to receive treatment of any form, including behavioral or 
pharmacological interventions (Grant et al. 2015). 
 While the number of adolescents diagnosed with alcohol dependence continues to 
increase, only a limited number of these patients receive treatment (Miranda and Treloar 
2016). Recently, initial studies have shown naltrexone may also be effective at reducing 
heavy drinking and alcohol craving in adolescents and young adults (Miranda et al. 2014; 
O’Malley et al. 2015). These results are promising for designing treatment interventions 
to reduce alcohol abuse in adolescence as a method to prevent progression to dependence 
later in life.  
Adolescent animal models 
 Animal models can be used to examine the neural correlates of alcohol use in 
adolescence and how these changes may be related to the risk of developing future 
alcohol problems. Most rodent models of alcohol use indicate adolescent animals 
consume more ethanol than adults, similar to epidemiological data (Bell et al. 2011; 
Broadwater et al. 2011; Doremus et al. 2005; García-Burgos et al. 2009; Vetter et al. 
2007). However, other studies have shown no differences or less intake in adolescents 
compared to adults (Schindler et al. 2014; Schramm-Sapyta et al. 2010; Siegmund et al. 
2005). A caveat is these models utilize nonoperant self-administration paradigms. 
Adolescence can be characterized by hyperphagia and hyperdipsia (Nance 1983), which 
may influence ethanol consumption in a free access paradigm. Indeed, studies that also 
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monitored food and water in addition to ethanol intake found increases in overall 
consumption (García-Burgos et al. 2009; Vetter et al. 2007).  
 Recently, our lab has begun to characterize operant ethanol self-administration 
behavior in adolescent rats (Doherty and Gonzales 2015). This model uses sweetened 
ethanol to facilitate stable operant responding within the short time period of adolescence 
in rats. Operant self-administration models have high predictive validity when examining 
potential pharmacological treatments for drug abuse (Carter and Griffiths 2009). 
Therefore, using operant ethanol self-administration in adolescent rats can be useful to 
determine efficacy of currently available and future treatments on a range of alcohol 
drinking behaviors. 
 
THE VENTRAL TEGMENTAL AREA 
Overview 
 A common mechanism shared by drugs of abuse is actions on the 
mesocorticolimbic dopamine system, which originates in the ventral tegmental area 
(VTA). Ethanol affects multiple targets in the brain, but the VTA is thought to be critical 
in the development of ethanol-related behaviors (Gonzales et al. 2004; Koob and Volkow 
2010). Dopamine neurons in the VTA are clearly involved in many drug-dependent 
behaviors, however recent evidence has also implicated GABA neurons in reward, 
aversion, and drug-dependent behaviors (Bocklisch et al. 2013; Creed et al. 2014; Fields 
et al. 2007; Nugent and Kauer 2008; Oliva and Wanat 2016). 
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 The largest neuronal population (55-65%) in the VTA consists of dopamine 
neurons (Margolis et al. 2006b; Swanson 1982). There is also a substantial proportion of 
GABA (25-30%) and glutamate (5%) neurons (Margolis et al. 2012; Nair-Roberts et al. 
2008). Additionally, recent evidence has shown some midbrain dopamine neurons can 
co-release GABA or glutamate (Stuber et al. 2010; Tritsch et al. 2014). The complexity 
of neuronal subpopulations and presence of co-release mechanisms suggests a more 
prominent role for neurotransmitters other than dopamine in the VTA, however future 
investigations are still needed to determine the physiological relevance.  
 In addition to heterogeneity in neuronal population, there is evidence supporting 
functional differences between the anterior VTA (aVTA) and posterior VTA (pVTA), 
first characterized by differences in GABAergic transmission (Ikemoto 2007; Sanchez-
Catalan et al. 2014). For example, rats will self-administer GABAA receptor antagonists 
into the aVTA but not the pVTA (Ikemoto et al. 1997; Ikemoto 2005). While some of the 
reinforcing properties associated with infusions into the aVTA were later attributed to 
diffusion to the supramammillary nucleus and the anatomical border between subregions 
was not always distinct, these earlier studies were critical to begin to understand the 
complexity within the VTA. Additional work suggests a dividing line between aVTA and 
pVTA of approximately -5.5 mm from bregma in rats to observe functional differences 
(Olson et al. 2005; Sanchez-Catalan et al. 2014; Schifirneţ et al. 2014). Overall, these 
studies implicate heterogeneity in GABA transmission within the VTA that, in turn, may 
influence aspects of ethanol reinforcement. 
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Role in ethanol reinforcement 
 Given its neuroanatomical connectivity, it is not surprising the VTA is involved in 
mediating many drug-dependent behaviors, including ethanol reinforcement. Activation 
of VTA dopamine neurons is considered one important aspect of ethanol reinforcement. 
Ethanol increases the firing rate of VTA dopamine neurons in vivo and using in vitro 
preparations (Brodie et al. 1990; Brodie et al. 1999; Gessa et al. 1985; Okamoto et al. 
2006). Microinjection of the D2/D3 agonist quinpirole into the VTA reduces operant 
responding for ethanol (Hodge et al. 1993). Rats will also directly self-administer ethanol 
into the pVTA, but not the aVTA, which has been suggested to depend on activation of 
VTA dopamine neurons (Rodd-Henricks et al. 2000; Rodd et al. 2004). Additionally, the 
activity of dopamine neurons in the VTA changes during development across 
adolescence, which may have important implications on early onset of problematic 
alcohol use. Dopamine neuron firing displays an inverted U-shaped curve, with the peak 
around puberty in rats (P45) (McCutcheon and Marinelli 2009; McCutcheon et al. 2012). 
 The role of dopamine in ethanol reinforcement has been extensively examined, 
however ethanol has also been shown to exert actions on other signaling mechanisms 
within the VTA. The effects of ethanol on GABA transmission and the endogenous 
opioid system in the VTA will be outlined below. 
Ethanol and GABA 
 Ethanol has been shown to induce neuroadaptive changes by modulating 
GABAergic plasticity in the VTA. Following a single ethanol injection (2 g/kg; i.p.) in 
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mice, there is a long-lasting potentiation of GABA release onto VTA dopamine neurons 
(Melis et al. 2002; Wanat et al. 2009). Acute ethanol (50 mM) enhanced action potential-
independent GABA release in slices of the VTA (Theile et al. 2008; Theile et al. 2009). 
Additionally, in vivo firing of VTA GABA neurons increased following acute low dose 
noncontingent intravenous ethanol administration and also during presentation of cues 
that predicted ethanol availability in a runway paradigm (Steffensen et al. 2009). 
Furthermore, chronic ethanol administration has been shown to enhance VTA GABA 
neuron firing rate (Gallegos et al. 1999) and increased spontaneous inhibitory 
postsynaptic currents (IPSCs) onto VTA dopamine neurons were recently observed 
following ethanol self-administration in adolescence (Schindler et al. 2016). 
 Conversely, in other reports acute ethanol has been shown to reduce VTA GABA 
neuron firing rate (Gallegos et al. 1999; Stobbs et al. 2004). Ye and colleagues reported 
ethanol (40 mM) application inhibited the firing rate of VTA GABA interneurons in 
slices and decreased GABA release (Xiao et al. 2007; Xiao and Ye 2008). However, 
more recently these authors concluded GABA release was enhanced by ethanol in the 
aVTA but reduced in the pVTA showing possible subregion specificity to the acute 
effects of ethanol (Guan et al. 2012). Interestingly, it has been suggested these 
differences may be due to the increased density of mu opioid receptor (MOR) expression 
in the pVTA compared to aVTA (Mansour et al. 1994; Mansour et al. 1995). Overall, 
further studies using freely moving animals are still needed to determine the effects of 
ethanol on GABA release in the VTA.  
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Opioid peptide system 
 There are three classes of opioid receptors (mu, delta, kappa), however the most 
consistent evidence from animal studies implicates the mu opioid receptor (MOR) in the 
regulation of alcohol drinking and reinforcement. MORs are located on dendrites and 
axon terminals of GABAergic neurons in the VTA (Garzon and Pickel 2001; Svingos et 
al. 2001). There is also dense MOR expression on terminals from rostromedial tegmental 
nucleus (RMTg) GABAergic inputs to the VTA (Jalabert et al. 2011; Jhou et al. 2009). 
Interestingly, recent work showed MOR knockout mice display increased basal dialysate 
GABA concentration (Chefer et al. 2009a), further supporting a role of tonic opioid 
regulation within the VTA (Spanagel et al. 1992).  
 Most developmental studies of the opioid system have focused on gestational and 
early postnatal periods prior to adolescence (Georges et al. 1998; Spain et al. 1985). 
Across adolescence, no differences were found in MOR density in the nucleus 
accumbens, dorsal striatum or prefrontal cortex in Long Evans rats (Ellgren et al. 2008). 
However, another study showed MOR expression reached adult levels shortly following 
birth, but MOR function was blunted up to age P30 (Talbot et al. 2005). These authors 
did not test ages between P30 and adulthood, therefore it is still unclear whether there are 
functional alterations in the opioid system during adolescence.    
Ethanol and opioids 
 The regulation of ethanol consumption by MORs involves multiple brain regions, 
including the VTA. Mice lacking MORs (Hall et al. 2001; Roberts et al. 2000) or 
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knockdown of MOR within the VTA (Lasek et al. 2007) both result in reduced ethanol 
intake. Microinjection of nalmefene, a nonselective opioid antagonist, into the VTA 
significantly reduced operant ethanol responding in alcohol-preferring (P) rats (June et al. 
2004). Acute ethanol has been shown to increase in vivo endogenous opioid peptide 
release including within the midbrain (Jarjour et al. 2009; Olive et al. 2001), and chronic 
ethanol consumption increased plasma beta-endorphin levels (Zalewska-Kaszubska et al. 
2008). 
  It is well accepted that nonselective opioid receptor antagonists reduce alcohol 
consumption and preference in animal models (Cowen et al. 1999; Froehlich et al. 1990; 
Mitchell et al. 2009; Sabino et al. 2013). Initial work to first show naltrexone reduced 
ethanol self-administration was performed in rhesus monkeys (Altshuler et al. 1980). 
Alcohol seeking behavior in rats is also reduced following opioid receptor antagonism 
(Ciccocioppo et al. 2002; Burattini et al. 2006). This is consistent with findings that 
opioid receptor antagonists attenuate ethanol-stimulated dopamine release in the nucleus 
accumbens during ethanol self-administration (Gonzales and Weiss 1998; Middaugh et 
al. 2003). Furthermore, recent work from our lab showed opioid receptor antagonists 
administered directly into the VTA reduced the delayed phase of dopamine release in the 
nucleus accumbens following acute ethanol administration (Valenta et al. 2013).  
 Few studies have examined whether naltrexone reduces ethanol consumption to a 
similar extent in adolescent animal models. Systemic naltrexone reduced two bottle 
choice (2BC) ethanol intake in adolescent alcohol-preferring (P) rats, with lower doses 
reported more effective compared to adult rats (Sable et al. 2006). However, there are 
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currently no direct comparisons between adolescent and adult rats using an operant 
ethanol self-administration model. Overall, these animal studies highlight part of the 
rationale behind use of the nonselective opioid receptor antagonist, naltrexone, to reduce 
relapse in human alcoholics, however the exact mechanism remains unknown (O’Malley 
et al. 1992; Volpicelli et al. 1992).  
 The original proposed mechanism for reinforcement following opioid receptor 
activation by ethanol and other drugs of abuse was due to inhibition of VTA GABA 
interneurons, which tonically inhibit dopamine neurons (Johnson and North 1992). 
However, MOR activation does not produce disinhibition of dopamine neuron firing in 
all cases and inhibition of local GABA interneurons may not be required for MOR 
activation of dopamine neurons (Margolis et al. 2003; Margolis et al. 2012; Theile et al. 
2011). Additionally, MORs on RMTg GABAergic inputs to the VTA are critical for the 
acute actions of opiates on dopamine neurons (Jalabert et al. 2011; Matsui and Williams 
2011; Matsui et al. 2014). Therefore, the two neuron model of opioid receptor reward 
proposed by Johnson and North (1992) in the VTA can be disputed in many cases.  
 Overall, both GABA and opioid signaling in the VTA are involved in ethanol 
reinforcement, however the direct or indirect actions of ethanol in vivo on these systems 
are still unclear. Extracellular neurotransmitter concentrations can provide valuable 
information on the result of changes in signaling, however the regulation of extracellular 






 Microdialysis is a sampling technique used to monitor neurotransmitters and other 
neuromodulators within the extracellular space. The microdialysis probe consists of a 
semipermeable membrane, often referred to as the “active area,” where small molecule 
analytes can diffuse across into or out of the perfusate according to concentration 
gradient, shown in Illustration 1.1. The primary advantage of using microdialysis in 
neuroscience is the ability to monitor dynamic changes in basal extracellular 
concentrations of multiple neurotransmitters in behaving animals. In addition, the probe 
membrane protects the tissue from the perfusate, prevents macromolecules from crossing 
into the sample and can be used to simultaneously deliver drugs to the extracellular 
space. However, disadvantages of microdialysis include limited temporal resolution and 
tissue damage resulting from probe implantation. Overall, microdialysis is widely used to 
quantify neurotransmitters implicated in neuropsychiatric disorders such as depression, 
pain, and drug addiction. 
 In conventional microdialysis, the probe is continuously perfused with a solution 
(e.g. artificial cerebrospinal fluid, ACSF) and neurotransmitters in the extracellular space 
diffuse across the membrane into the perfusate. The rate of analyte removal from the 
probe exceeds the rate of analyte replacement to the membrane surface within the 
extracellular space at flow rates used in most experiments (Chefer et al. 2009b). 
Therefore, the concentration in the dialysate sample represents a fraction of the actual 
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concentration in the extracellular fluid. The ratio between the dialysate concentration and 
the actual extracellular concentration is termed the extraction fraction, relative recovery 
or probe efficiency. Despite only measuring a fraction of the extracellular concentration, 
conventional microdialysis is often suitable for examining changes from an averaged 
baseline following pharmacological manipulations. However, even if knowing the 
absolute extracellular concentration of an analyte is not necessary, it can be useful to 
draw a relationship between dialysate and extracellular concentration to use as reference 
point or when determining the mechanism of action of drugs.  
 Flow rate, membrane surface area, analyte characteristics (e.g. molecular weight), 
and the resistance of the tissue all influence probe recovery. Early studies used in vitro 
probe calibration to extrapolate extracellular concentration in vivo but this method is not 
always accurate because the diffusion resistance of tissue differs from the diffusion 
resistance in solution (Benveniste et al. 1989; Bungay et al. 1990; Chefer et al. 2009b). 
For neurotransmitters, tissue resistance is influenced by active processes such as uptake 
(Bungay et al. 1990). Changes in the physiological characteristics of the tissue such as 
rate of analyte clearance (e.g. uptake or metabolism) and tortuosity, as well as 
pharmacological treatments can lead to changes in extraction fraction during an 
experiment. Indeed, Parsons et al. showed that extraction fraction can be altered 
independent of extracellular concentration (Parsons et al. 1991). Therefore, dialysate 
measurements may not reflect changes in extracellular concentration due to the influence 




















Illustration 1.1 Overview of brain microdialysis 
Semipermeable membrane of probe allows neurotransmitters and neuromodulators to 






 Quantitative (no net flux) microdialysis was developed as a method to determine 
in vivo extraction fraction. This method includes the analyte in various concentrations in 
the perfusate to bracket the anticipated in vivo extracellular concentration (Justice 1993; 
Lonnroth et al. 1987). When the analyte concentration in the perfusate is less than the 
extracellular concentration, there is a net gain of analyte (via diffusion) into the dialysate 
sample. Similarly, when the analyte concentration in the perfusate is greater than the 
extracellular concentration there is a net loss of analyte from the probe. The known 
concentrations of analyte in the perfusate are plotted against the net gain or loss of 
analyte in the dialysate. The point of no net flux across the probe membrane is the x-
intercept of the regression, and represents the extracellular concentration in the tissue 
(Illustration 1.2). The slope of the regression represents the in vivo extraction fraction. 
Quantitative microdialysis was also adapted for transient conditions to measure time-
dependent changes of in vivo extraction fraction (Olson and Justice 1993). This extension 
of the method utilizes separate groups of animals for each analyte concentration and has 
been used to show in vivo extraction fraction can change over time following 
pharmacological manipulation (Cosford et al. 1994; Olson and Justice 1993). 
 The in vivo extraction fraction has been described as sensitive to changes in 
neurotransmitter clearance for monoamines (Bungay et al. 1990; Bungay et al. 2003; 
Morrison et al. 1991). For example, using pharmacological manipulations in the nucleus 
accumbens, it was shown that only treatments that reduced dopamine uptake but not 
synthesis, release or metabolism altered in vivo extraction fraction (Smith and Justice 
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1994). Additionally, 6-hydroxydopamine lesions in the nucleus accumbens reduced in 
vivo extraction fraction by approximately 50% (Parsons et al. 1991). Subsequent studies 
extended the relationship between clearance and in vivo extraction fraction to 




Illustration 1.2 Quantitative (no net flux) microdialysis 
The x-intercept from the regression (red symbol) is the point of no net flux across the 
probe membrane and represents the extracellular concentration. Adapted from 





 The regulation of amino acid neurotransmitters glutamate and GABA in the 
extracellular space is largely dependent on uptake from both neurons and astrocytes 
(Zhou and Danbolt 2013). Therefore, whether in vivo extraction fraction is sensitive to 
changes in clearance for these neurotransmitters is still a matter of debate. Local 
application of the glutamate uptake blocker trans-pyrrolidine-2,4-dicarboxylic acid 
(tPDC) through the microdialysis probe significantly reduced in vivo extraction fraction 
when measured using steady-state quantitative microdialysis in the hippocampus (Chefer 
et al. 2011). However, the majority of studies suggesting in vivo extraction fraction 
represents glutamate clearance have investigated basal dynamics following chronic drug 
or ethanol exposure. For example, chronic ethanol administration was shown to reduce in 
vivo extraction fraction and [3H]-glutamate uptake in slices (Melendez et al. 2005). 
Experiments have reported reduced in vivo extraction fraction either coincides with 
reduced (Das et al. 2015) or no change (Melendez et al. 2005; Pati et al. 2016) in protein 
expression of glutamate transporters. Indeed, a recent study reported reduced [3H]-
glutamate uptake in slices and in vivo using biosensors in the nucleus accumbens core 
following heroin self-administration (Shen et al. 2014). However, this study also reported 
in vivo extraction fraction measured using microdialysis was significantly increased. 
Together, these results largely suggest the relationship between in vivo extraction fraction 
and glutamate clearance remains unclear.  
 While there is some evidence on the regulation of glutamate in the extracellular 
space, there are few investigations on the regulation of extracellular GABA 
concentration. Quantitative microdialysis has been used to measure GABA in the nucleus 
 
 17 
accumbens (Xi et al. 2003), however there are no reports of basal extracellular GABA 
concentration within the VTA. Additionally, inhibiting GABA transporters increases 
dialysate GABA concentration (Chefer et al. 2009a; Vihavainen et al. 2008) but whether 
changes in GABA uptake are reflected by in vivo extraction fraction is currently 
unknown. 
Measuring extracellular GABA 
 The basal concentrations of most neurotransmitters measured using microdialysis 
are sensitive to the sodium channel blocker tetrodotoxin (TTX) and calcium omission 
from the perfusate, which meets the requirements of exocytotic release from neurons. In 
contrast, basal concentrations of amino acid neurotransmitters including GABA are not 
reliably responsive to these manipulations (Timmerman and Westerink 1997). 
Additionally, high affinity GABA transporters prevent most GABA from escaping the 
synaptic cleft into the extracellular space (Schousboe et al. 2013). This led to the 
assumption that GABA measured in microdialysis was derived from mostly non-neuronal 
sources. However, recent work identified specific chromatographic conditions were 
required for accurate detection of GABA in dialysates, emphasizing that earlier findings 
may have misidentified or quantified GABA with other contaminants (Rea et al. 2005). 
Under optimal conditions, extracellular GABA was responsive to TTX and calcium 
omission, suggesting a significant portion was of synaptic origin. These results and others 
have suggested that microdialysis can detect GABA from neuronal sources, although 
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synaptic spillover into the extracellular space is likely buffered by astrocyte networks 
(Del Arco et al. 2003; van der Zeyden et al. 2008).  
Extracellular GABA in the VTA 
 Dialysate GABA concentrations in the VTA are typically reported to be lower 
than most brain regions, however a wide range is described in the literature (Fliegel et al. 
2013). Despite low concentrations and the challenges in separation of GABA mentioned 
previously, there are studies showing acute or chronic drugs of abuse can alter dialysate 
GABA concentration in the VTA. 
 Acute 3,4,-methylenedioxymethamphetamine (MDMA) has been shown to 
increase dialysate GABA concentration, which was completely blocked by co-
administration of TTX (Bankson and Yamamoto 2004). Nicotine administration 
increased VTA GABA in naïve rats but not in rats with a history of nicotine self-
administation (Buczynski et al. 2016). Local morphine delivered through the 
microdialysis probe significantly reduces VTA GABA concentration (Klitenick et al. 
1992; Sotomayor et al. 2005). Interestingly, the decrease in dialysate GABA 
concentration from systemic morphine was only observed using nipecotic acid to induce 
neuronal spillover (Ojanen et al. 2007; Vihavainen et al. 2008). Overall, these studies 
illustrate changes in dialysate GABA concentration in the VTA are implicated in the 
mechanism of some drugs of abuse. 
 Differences in GABA release following acute ethanol have been reported using 
electrophysiology, however microdialysis experiments have been unsuccessful in 
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determining in vivo effects of ethanol in the VTA. For example, acute ethanol injections 
(1 or 2 g/kg) did not alter dialysate GABA concentration in naïve or rats treated with 
chronic morphine injections (Kemppainen et al. 2010; Ojanen et al. 2007; Yan et al. 
2005). Oral ethanol gavage also did not modify dialysate GABA concentration (Cowen et 
al. 1998). As mentioned above for systemic morphine, inhibiting GABA uptake is a 
potential method to allow better characterization within the extracellular space of whether 
changes in neuronal release occur following acute ethanol administration.  
 Overall, studies have shown changes in extracellular GABA occur following 
acute or chronic treatment with some, but not all, drugs of abuse. Changes in extracellular 
GABA concentration in the VTA may contribute to the development of drug-related 
behaviors. However, there is limited evidence investigating the regulation basal 
extracellular GABA concentration in the VTA and how these mechanisms may be 













Aim 1: To investigate the effects of systemic administration of naltrexone on operant 
ethanol self-administration behaviors in adolescent and adult rats 
 
 Naltrexone reduces ethanol self-administration in adult rats and some clinical 
populations. Significant neurobiological changes occur during development, which may 
influence ethanol self-administration and efficacy of treatments during adolescence. 
Additionally, there are few investigations using an operant ethanol self-administration 
model in adolescent animals. Therefore, in Aim 1 we sought to determine the effects of 
systemic naltrexone on operant ethanol self-administration, motivation to consume 
ethanol and “relapse” to ethanol seeking in rats that began drinking in adolescence 
compared to adulthood. 
 
Aim 2: To develop a high sensitivity method for quantifying GABA in microdialysis 
samples using fluorescence detection of an OPA/sulfite derivative 
 
 A proposed mechanism for naltrexone’s ability to reduce ethanol intake involves 
antagonism of mu opioid receptors on GABA interneurons in the VTA. Changes in 
inhibitory signaling have been implicated in the mechanism of drugs of abuse, including 
ethanol. However, there are few investigations measuring whether these changes translate 
to acute or chronic alterations in extracellular GABA concentration in the VTA. 
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Additionally, there are challenges with accurate detection of GABA in the VTA and 
separation using high performance liquid chromatography (HPLC). Therefore, we began 
developing methods to reliably quantify GABA in microdialysis samples. During this 
process, it became clear that fluorescence detection required less maintenance than 
electrochemical detection due to the high working potential necessary for electrochemical 
detection of GABA.  
 Our initial experiments conducted using electrochemical detection utilized a 
precolumn derivatization protocol with o-phthalaldehyde and sulfite to produce an 
electroactive GABA derivative. This protocol is often preferred to using an organic thiol 
as the nucleophile due to increased stability of the derivative and lack of pungent odor. 
However, OPA/sulfite GABA derivatives were reported to be less fluorescent than thiol 
derivatives and incompatible for use with sensitive applications such as in vivo 
microdialysis. Therefore, the experiments in Aim 2 were conducted to develop a reliable 
method to use fluorescence detection of an OPA/sulfite GABA derivative. 
 
Aim 3: To determine if changes in GABA uptake are reflected by in vivo extraction 
fraction using quantitative microdialysis in the VTA 
  
 There is a wide range of basal GABA concentrations reported for the VTA using 
conventional microdialysis. Additionally, while changes in dialysate GABA 
concentration in the VTA have been observed following acute or chronic treatment with 
some drugs of abuse, it is unknown how the regulation of extracellular GABA contributes 
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to the interpretation of conventional microdialysis data. These factors may influence 
further investigation in determining the actions of ethanol on GABA concentration in the 
VTA using microdialysis. In vivo extraction fraction is considered an indirect measure of 
clearance for monoamine neurotransmitters, however it remains to be determined 
whether this is similar for amino acid neurotransmitters such as GABA. Therefore, in 
Aim 3 we conducted experiments to investigate the effects of inhibiting GABA uptake in 





















Chapter 2: Naltrexone reduces operant sweetened ethanol self-
administration, motivation to obtain ethanol, and relapse behavior in 
Long Evans rats that begin drinking in adolescence or adulthood 
 
ABSTRACT 
 Background: Alcohol is widely abused in adolescence and contributes to 
significant adverse consequences in this population. However, treatment rates for 
adolescents remain low in part due to lack of data on the efficacy of current medications. 
Naltrexone, a nonselective opioid antagonist, is effective at reducing ethanol (EtOH) 
consumption in adult animal models and select clinical populations. However, limited 
research exists on the efficacy of naltrexone in individuals who began drinking in 
adolescence. 
 Methods: Adolescent (postnatal day 36 at first EtOH exposure) and adult Long 
Evans rats were tested for the ability of naltrexone (0, 0.25 or 0.5 mg/kg, s.c.) to reduce 
intake and motivation to consume sweetened EtOH (10% sucrose + 10% EtOH; 10S10E) 
using a progressive ratio (PR) schedule of reinforcement. Following PR testing and 13 
days of forced abstinence, rats were tested for the ability of naltrexone to reduce 
“relapse” EtOH seeking. Control rats drank 2% sucrose (2S) throughout the experiment. 
 Results: Naltrexone significantly reduced sweetened EtOH intake and motivation 
to obtain sweetened EtOH in both adolescent and adult rats during the PR session. 
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Naltrexone significantly reduced “relapse” EtOH seeking after abstinence regardless of 
whether self-administration began in adolescence or adulthood. Rats that began operant 
sweetened EtOH self-administration in adolescence pressed the lever significantly fewer 
times across all naltrexone doses compared to adults during the “relapse” test. Naltrexone 
did not alter operant behavior for sucrose in control rats.  
 Conclusions: Our results show naltrexone is effective at reducing sweetened 
EtOH intake, motivation to obtain EtOH and “relapse” behavior in an operant self-
administration model using adolescent rats. Age of initiation of operant EtOH self-
administration may contribute to the expression of EtOH seeking behavior. Collectively, 
these data support the use of naltrexone as a potential treatment option for late 















 Alcohol use in adolescence is an increasing health concern as earlier age of onset 
is significantly associated with future rates of alcohol dependence and development of 
alcohol dependence at a younger age (DeWit et al. 2000; Hingson et al. 2006). The 
number of adolescent patients diagnosed with alcohol use disorder (AUD) is growing, 
however only approximately 10% receive treatment in part due to lack of data on the 
efficacy of currently available treatments in this population (SAMHSA 2015; Swendsen 
et al. 2012). Although research has focused on expanding pharmacotherapy treatment 
options for adults, little is known about whether currently available treatments are 
effective in adolescents (reviewed in Miranda and Treloar 2016).  
 Naltrexone is a nonselective opioid antagonist approved by the U.S. Food and 
Drug Administration for treatment of AUD in adults. In patients with alcohol 
dependence, naltrexone decreases relapse to heavy drinking and alcohol intake in some 
(O’Malley et al. 1992; Sinclair 2001), but not all studies (Krystal et al. 2001). More 
recently, an initial study in adolescents showed promising effects of naltrexone to reduce 
heavy drinking and alcohol craving (Miranda et al. 2014). A larger randomized clinical 
trial found naltrexone reduced the number of drinks during drinking episodes in young 
adults aged 18-25 years old (O’Malley et al. 2015). One challenge of clinical trials is 
reliance on alcohol use self-assessments, which can be more problematic if requiring 
adult subjects to estimate previous history of alcohol intake in adolescence. However, 
investigating naltrexone using relevant adolescent animal models would provide more 
insight into possible age-specific effects on ethanol-associated behaviors and an accurate 
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measure of ethanol consumption during adolescence. Operant models of alcohol use are 
considered the “gold standard” when testing the efficacy of a treatment because of their 
high predictive validity (Carter and Griffiths 2009). Operant ethanol self-administration 
models are common using adult animals, but rarely reported in adolescents due to the 
limited period of adolescence in rats (approximately 20 days in males) and initial 
aversive properties of ethanol. Naltrexone has been shown to reduce alcohol seeking, 
consumption and cue-induced reinstatement in adult rats (Burattini et al. 2006; 
Ciccocioppo et al. 2003; Gonzales and Weiss 1998; Hay et al. 2013; Henderson-
Redmond and Czachowski 2014; Katner et al. 1999). However, whether naltrexone 
reduces ethanol consumption in adolescent rats using an operant self-administration 
model is currently unknown.  
 We recently developed an operant sweetened ethanol (EtOH) self-administration 
model in adolescent Long Evans rats (Doherty and Gonzales 2015). Here, we 
investigated whether systemic naltrexone administration would have similar efficacy to 
reduce ethanol consumption, motivation to obtain ethanol and “relapse” behavior in rats 







MATERIALS AND METHODS 
Animals 
 Male Long Evans rats (Charles River, Raleigh, NC) arrived at postnatal day (P) 
22 (43-67 g; shipped with lactating dam) or P60-65 (290-301 g). Rats were pair housed 
by age (25°C; 12 h light/dark schedule; lights on 0700 h) and handled daily for at least 
one week before training. Food and water were available ad libitum in home cages, 
except for brief water deprivation prior to lever press training. Following training, 
operant sessions occurred once per day at the same time (0900-1600 h), five days per 
week. Adolescent rats were at P36 at first ethanol exposure, which corresponds to early 
adolescence before the onset of puberty in male rats (Lewis et al. 2002; McCutcheon and 
Marinelli 2009; Spear 2000). All procedures complied with the National Institutes of 
Health Guide for Care and Use of Laboratory Animals (8th Ed., 2011) and were approved 
by the Institutional Animal Care and Use Committee of the University of Texas at 
Austin. 
Drugs 
 Drinking solutions (2% or 10% sucrose (w/v) (2S; 10S) or 10% sucrose + 10% 
ethanol (v/v) (10S10E)) were made fresh twice weekly using 95% ethanol (AAPER, 
Shelbyville, KY), ultra-pure sucrose (MP Biomedicals, Solon, OH), and deionized water. 
Naltrexone hydrochloride (Sigma Aldrich, St. Louis, MO) was dissolved in sterile saline 
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for subcutaneous injection (0.25 or 0.5 mg/kg, at 1.0 ml/kg). Control saline injections 
were matched for volume (1.0 ml/kg). 
Experimental design 
 Rats were separated into two drinking groups within each age group (10S10E and 
2S) after the initial training phase. Following operant ethanol or sucrose self-
administration (Fig. 2.1), naltrexone was injected subcutaneously 30 minutes prior to start 
of PR and “relapse” operant testing (defined below). The doses of naltrexone (0.25 and 
0.5 mg/kg, s.c.) were chosen because previous reports showed these doses reduced 
operant ethanol self-administration (Czachowski and DeLory 2009; Gonzales and Weiss 
1998; Hay et al. 2013). Naltrexone doses were assigned in a pseudo-random design 
between PR and “relapse” tests. We used 2S as the control reinforcing solution to 
approximate the amount of operant responding for 10S10E during the PR session. 
 Our previous data indicated a subset of adolescent rats show little or no detectable 
blood ethanol concentration (BEC; < 5 mg/dl) following operant ethanol self-
administration at intake levels which produce detectable BECs in adult rats (Doherty and 
Gonzales 2015). Nondetectable BECs following operant self-administration suggested 
some rats may not be experiencing the central reinforcing effects of ethanol consumption 
and if so, could interfere with our interpretation of naltrexone data in the experiment. 
Therefore, we used BEC data to assign subjects into three groups (adult, adolescent, and 
nondetectable (ND) adolescent). The two adolescent groups were assigned using a 
criterion for BEC to be considered detectable (> 5 mg/dl). Data were first analyzed for 
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differences between adolescent BEC subgroups. If no significant differences occurred 
between adolescent subgroups, data were combined and analyzed based on age of onset 
(adolescent vs. adult) of ethanol self-administration.  
Operant behavioral testing  
 Operant behavioral testing was conducted as previously described (Doherty and 
Gonzales 2015). Briefly, there were four phases in the experiment (Fig. 1). The four 
phases of the experiment were: 1) lever training using 10S; 2) appetitive/consummatory 
model; 3) fixed ratio (FR) and progressive ratio (PR) testing; and 4) “relapse” of seeking 
behavior after 13 days of forced abstinence in the home cage. In this study we did not 
extinguish operant behavior. We define “relapse” as the return of operant responding in 
the ethanol self-administration context after an abstinence period. The 
appetitive/consummatory operant model consists of a 5-minute wait period (appetitive-
seeking phase), then a response requirement of 4 lever presses, followed by 20-minutes 
of continuous access to the drinking solution (consummatory phase). The FR2 schedule 
of reinforcement was implemented prior to testing on a PR schedule of reinforcement to 
adjust the rats to a higher response requirement and limited access to the drinking 
solution (10 sec for each reinforcement). The PR session was 60 minutes and breakpoint 
values were determined as an index of motivation to obtain the drinking solution. The 
progression of response requirements was similar to Walker and Koob (2007). After 13 
days of forced abstinence, a 20-minute “relapse” test was performed to measure lever 
press responding under extinction conditions; rats could see and smell the drinking 
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solution, but they could not drink, and lever presses only resulted in illumination of the 
cue light.  
Blood ethanol concentration (BEC) after operant self-administration  
 The protocol to measure BEC was previously described (Doherty and Gonzales 
2015). Briefly, during the last three days of the appetitive/consummatory operant phase 
(Fig. 2.1), we sampled blood from most rats in the 10S10E group either at 12 min 
(allowed 5 min to drink; n=15), 22 min (allowed 15 min to drink; n=15), or 35 min 
(allowed 20 min to drink; n=26) after the start of the operant session. Blood was collected 
from the saphenous vein under light isoflurane anesthesia. The ethanol content (mg/dl) in 
10 μl of blood (mixed with 90 μl saturated saline, tested in duplicate or triplicate) was 
measured using gas chromatography with flame ionization detection. The majority of 
samples were analyzed using a Scion 436 gas chromatograph (Bruker, Netherlands), 
Varian 8200 headspace autosampler and hydrogen generator (Model 20H-MD, Parker 
Hannifin, England) to produce hydrogen as the carrier gas. Data were recorded using 
CompassCDS (Bruker, Netherlands) software. A subset of animals (adolescents, n=9; 
adults, n=8) were analyzed using a previous system detailed in Carrillo et al. (2008). 
Statistics 
 Ninety rats were included in this study. Sweetened ethanol self-administration 
prior to PR testing from 35 rats was previously reported in Doherty and Gonzales (2015). 
Data from these 35 rats were combined with new data to generate Figure 2.2. Also, BEC 
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data from 19 of the previously reported 35 rats were used to help classify the adolescent 
groups into detectable and nondetectable BEC groups as described above in the 
Experimental design section. Two adolescents did not establish stable self-administration 
and were excluded (consumption of <0.3 g/kg ethanol in 4 out of last 5 
appetitive/consummatory sessions.) BECs were not sampled from 4 adults included in the 
behavioral analyses. Two adult rats were excluded from the BEC analysis due to lower 
consumption (<0.3 g/kg ethanol) only on the BEC sampling day, but they were included 
in later behavioral analyses. For the PR session, 2 adults in the sweetened ethanol group 
were excluded due to incorrect injections. For the “relapse” test, one adolescent in the 
sucrose control group was excluded due to unrelated death during the abstinence period. 
BEC analyses  
 Ethanol consumption on BEC test day and BEC data were analyzed using one-
way analysis of variance (ANOVA). Pearson correlation and linear regression were used 
to determine whether ethanol dose (g/kg) consumed and BEC were related for each age 
group.  
Behavioral analyses 
 Ethanol consumption (g/kg) was analyzed in the 10S10E group using mixed 
measures ANOVA, with BEC group as the between subjects factor, and session as a 
within subjects repeated measure. Cumulative ethanol intake prior to PR testing (sessions 
1-14; g/kg) was analyzed using one-way ANOVA between BEC group. Behavioral 
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measures in both PR and “relapse” tests were analyzed using an ANOVA with BEC 
group, age, and naltrexone dose (0, 0.25, 0.5 mg/kg) as between subject factors. For all 
analyses, Bonferroni’s post hoc comparisons were used as appropriate, and results with 
p<0.05 were assigned significance.  
 
RESULTS 
Sweetened ethanol consumption  
 Sweetened ethanol consumption increased across sessions throughout the 
experiment for all groups (F13,767=23.52, p<0.001). Prior to the BEC test, there were no 
significant differences in ethanol intake across operant sessions between adolescent 
subgroups, although a trend existed for ND adolescents to consume less ethanol 
(F1,34=3.48, p=0.07). When adolescent subgroups were combined, there were no 
significant differences in ethanol intake across operant sessions prior to BEC test between 
adolescent and adult rats (Fig. 2.2A operant sessions 1-7; F1,60=0.74, ns). However, when 
ethanol intake was totaled prior to PR test, there were significant differences between 
adolescent subgroups (F1,34=11.02, p<0.01). Total ethanol consumption history was 
significantly different between the 3 groups (F2,59=6.13, p<0.01). Adolescent rats with 
nondetectable BECs consumed significantly less total ethanol prior to the PR test (Fig. 




Blood ethanol concentration (BEC) after operant sweetened ethanol self-
administration 
 Blood samples were taken at three different time points (12, 22, or 35 minutes) 
after the start of drinking 10S10E in the appetitive/consummatory model, and we 
previously reported BEC data from the 12- and 22-minute sampling points (Doherty and 
Gonzales, 2015). Our previous work indicated 35 minutes following the start of drinking 
was the most appropriate point to measure peak BEC so we used this group for further 
analyses. For the 35-minute samples, in agreement with our previous findings (Doherty 
and Gonzales 2015), 58% of adolescent rats had little or no detectable ethanol in their 
blood (BEC < 5 mg/dl) despite drinking at least 0.3 g/kg ethanol in the operant session. In 
contrast, all adult rats that consumed at least 0.3 g/kg showed detectable BECs. Ethanol 
consumption on the BEC test day significantly differed between 3 groups (F2,23=18.15, 
p<0.001). ND adolescent rats drank significantly less ethanol (0.8 ± 0.2 g/kg) on BEC 
test day compared to adult (1.4 ± 0.2 g/kg) and adolescent (1.8 ± 0.6 g/kg) rats with 
detectable BECs (p<0.01). At the 35-minute sampling time, BEC and ethanol dose (g/kg) 
consumed were significant correlated in both adults and adolescents with detectable 
BECs (Fig. 2.3; adults, F1,7=9.29, p<0.05; adolescents, F1,5=7.64, p<0.05). 
Effect of naltrexone on PR schedule of reinforcement 
 Following two weeks of operant sweetened ethanol self-administration with the 
appetitive/consummatory model and four days using a FR2 schedule of reinforcement, 
rats underwent a PR session to test the ability of naltrexone (0, 0.25, 0.5 mg/kg; s.c.) to 
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reduce ethanol intake and breakpoint value in a PR test. No significant differences were 
found between the adolescent subgroups on sweetened ethanol consumption (F1,30=0.02, 
ns) or breakpoint value (F1,30=0.49, ns) in the PR test. Therefore, age of initiation of 
operant sweetened ethanol self-administration was used to assess the effects of naltrexone 
during the PR test. Naltrexone treatment significantly reduced sweetened ethanol intake 
during the PR session in both adolescent and adults (Fig. 2.4A; F2,54=10.70, p<0.001). 
Post hoc tests revealed both doses of naltrexone significantly reduced sweetened ethanol 
intake (p<0.01). Naltrexone also significantly reduced breakpoint values in both age 
groups (Fig. 2.5A; F2,54=4.41, p<0.05), with the 0.5 mg/kg dose exhibiting a significant 
reduction during post hoc analysis (p<0.05). In control rats that only drank 2S throughout 
the experiment, naltrexone or age did not significantly affect sucrose intake (g/kg) during 
the PR session (Fig. 2.4B; NTX F1,24=0.27, ns; age F1,24=2.80, ns). Naltrexone also did not 
affect sucrose breakpoint values in control rats (Fig. 2.5B; NTX F1,24=0.04, ns; age 
F1,24=0.04, ns).  
Effect of naltrexone on “relapse” of sweetened ethanol or sucrose after abstinence  
 The efficacy of naltrexone to reduce “relapse” behavior was examined after 13 
days of forced abstinence from sweetened ethanol or sucrose. No significant differences 
were found between adolescent subgroups in total lever presses during the “relapse” test 
(F1,30=1.27, ns). Naltrexone treatment significantly reduced total lever presses during the 
“relapse” test in both age groups (Fig. 2.6A; F2,56=4.48, p<0.05), with the 0.5 mg/kg dose 
exhibiting the most robust reduction during post hoc analysis (p<0.05). Interestingly, rats 
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that began drinking sweetened ethanol in adolescence pressed significantly fewer times 
regardless of naltrexone treatment (main effect age; F1,56=4.85, p<0.05). In control rats 
with a history of drinking 2S, naltrexone did not affect sucrose lever presses (Fig. 2.6B; 
F1,23=0.33, ns) although a trend existed for the adolescent group to press more times than 




















Figure 2.1  Timeline of operant sweetened ethanol self-administration in adolescent and 
adult rats  
Adolescents arrived at postnatal day (P) 22, adults ~P62. All rats were initially trained on 
a 10% sucrose solution (10S). Sweetened ethanol (EtOH) (10% sucrose + 10% EtOH 
[10S10E]) self-administration began at P36 for adolescents, ~P76 for adults. Rats were 
tested on appetitive/consummatory, fixed ratio 2 (FR2), progressive ratio (PR), and 
“relapse” models of operant self-administration. Blood EtOH concentration (BEC) was 
measured across the last three days of appetitive/consummatory sessions. Rats received 
naltrexone ([NTX] 0, 0.25, 0.5 mg/kg; subcutaneous) 30 minutes prior to PR and 
“relapse” sessions. Control rats drank 2% sucrose (2S) throughout the experiment. Figure 
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Figure 2.2  Amount of sweetened ethanol consumed prior to the blood ethanol 
concentration test and total ethanol consumed (g/kg) prior to the progressive 
ratio test 
(A) Sweetened ethanol intake prior to blood ethanol concentration (BEC) test (sessions 1-
7) did not differ between age groups. (B) When ethanol intake was totaled from all 
operant models prior to progressive ration (PR) test (sessions 1-14), adolescents with no 
detectable BEC (Adol ND) drank significantly less sweetened ethanol than adolescents 
with detectable BECs (** indicates p<0.01). For both panels data presented as mean ± 
sem, and group n is shown within bars. 









































     
Figure 2.3  Blood ethanol concentration (BEC) in adolescents and adults 35 minutes 
after the start of drinking sweetened ethanol in an operant self-
administration session 
A large proportion of adolescents had little or no detectable ethanol (EtOH) in their blood 
after drinking sweetened EtOH (nondetectable (ND) adolescent; BEC < 5 mg/dl; grey 
squares). In contrast, all of the adults (black circles, solid line), and half of adolescents 
(open squares, dotted line) had BEC > 5 mg/dl, and their BEC significantly correlated 
with EtOH intake (adolescent p<0.05; adult p<0.05). 























Figure 2.4  Naltrexone treatment on sweetened ethanol or sucrose intake during the 
progressive ratio test 
(A) Naltrexone significantly reduced sweetened ethanol (EtOH) consumption in the 
progressive ratio (PR) test in adolescents and adults (** indicates p<0.01, *** indicates 
p<0.001). 10S10E=10% sucrose + 10% ethanol. (B) Naltrexone did not alter sucrose 
consumption during the PR test in control rats. 2S=2% sucrose. For both panels data 



















































Figure 2.5  Naltrexone treatment on progressive ratio (PR) breakpoint values in 
sweetened ethanol or control sucrose groups 
(A) Naltrexone significantly reduced breakpoint values of adolescents and adults drinking 
sweetened ethanol during the PR test (* indicates p<0.05). 10S10E=10% sucrose + 10% 
ethanol. (B) Naltrexone did not alter breakpoint values of control sucrose groups during 
the PR test. 2S=2% sucrose. For both panels data presented as mean ± sem, and group n 






































Figure 2.6  Naltrexone treatment on “relapse” of ethanol or sucrose seeking after a 
period of abstinence 
(A) Naltrexone significantly reduced “relapse” of 10S10E-paired lever presses in 
adolescents and adults with a history of drinking sweetened ethanol (* indicates p<0.05). 
Rats that began drinking sweetened ethanol in adolescence pressed significantly fewer 
times across all doses compared to rats that began drinking in adulthood (# indicates 
p<0.05). 10S10E=10% sucrose + 10% ethanol. (B) Naltrexone did not alter “relapse” of 
2S-paired lever presses in control group with a history of drinking sucrose. 2S=2% 
















































 The results of this study are the first evidence to indicate that systemic naltrexone 
is effective in reducing operant sweetened ethanol consumption, motivation to obtain 
sweetened ethanol and “relapse” behavior in rats that began operant sweetened ethanol 
self-administration in adolescence. Naltrexone significantly reduced ethanol intake and 
breakpoint value in adolescents during the PR test. In the “relapse” test following 13 days 
of forced abstinence, naltrexone also significantly reduced lever presses for ethanol in 
rats that began operant sweetened ethanol self-administration in adolescence. 
Interestingly, age of onset of ethanol self-administration may influence expression of 
“relapse” behavior as rats that began operant sweetened ethanol self-administration in 
adolescence pressed fewer times in the “relapse” test compared to adults. As a positive 
control, naltrexone also significantly reduced ethanol intake, breakpoint and “relapse” 
behavior in rats that began operant sweetened ethanol self-administration in adulthood. 
All of the reported effects of naltrexone were specific to sweetened ethanol, as naltrexone 
did not affect sucrose consumption, motivation to obtain sucrose or “relapse” behavior in 
control rats.  
 The present study is the first to show that naltrexone reduces sweetened ethanol 
intake and motivation to obtain sweetened ethanol using a PR schedule of reinforcement 
in rats that began sweetened ethanol operant self-administration in adolescence. Here we 
extend published findings in adult rats that naltrexone significantly decreases operant 
ethanol self-administration and breakpoint value (Ciccocioppo et al. 2003; Gonzales and 
Weiss 1998; Hay et al. 2013; Henderson-Redmond and Czachowski 2014) to now 
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include similar findings in adolescent rats. Naltrexone has previously been shown to 
reduce ethanol consumption in adolescent alcohol-preferring (P) rats using a two-bottle 
choice paradigm (Sable et al. 2006). Our data extend these findings to indicate that 
naltrexone is effective at reducing sweetened ethanol intake in adolescents at similar 
levels to adult rats using an operant self-administration model, known to have high 
predictive validity for testing treatment efficacy (Carter and Griffiths 2009). Importantly, 
in our study rats that began operant sweetened ethanol self-administration in adolescence 
were 54 days old during the PR test. Some studies suggest the range of 28-42 days as an 
estimate of “adolescence” in rodents (Spear 2000). However, many neural circuits, 
including midbrain dopamine neurons that are implicated in ethanol-related behaviors, 
are still undergoing maturation past this age range (McCutcheon and Marinelli 2009).  
 The mechanisms by which naltrexone suppresses ethanol self-administration 
behavior has been suggested to involve antagonism of opioid receptors in adult models 
(Gonzales and Weiss 1998; Herz 1997).  Specifically, the mu opioid receptor has been 
linked to motivation to consume ethanol in adult rodent models (Herz 1997; Richard and 
Fields 2016). Limited evidence suggests that opioid receptor signaling is present in 
relevant brain areas in adolescents similar to that in adults (Ellgren et al. 2008; Palm and 
Nylander 2014). Therefore, it is likely that the reduction of operant ethanol self-
administration in adolescents and young adults that we report here is due to opioid 
receptor antagonism similar to the hypothesized mechanism for adults. Opioid 
antagonists have also been shown to decrease ethanol intake in preweanling rats (Chotro 
and Arias 2003; Hallmark and Hunt 2004). However, the precise mechanisms underlying 
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the reduction in operant ethanol self-administration and breakpoint value by systemic 
naltrexone in adolescence remain unknown.  
 Our study also provides the first evidence that naltrexone significantly reduces 
lever presses for sweetened ethanol in an operant “relapse” test in rats that began drinking 
in adolescence. Systemic naltrexone has previously been shown to decrease cue- and 
context-induced reinstatement for ethanol seeking following extinction in adult rats 
(Burattini et al. 2006; Ciccocioppo et al. 2003; Katner et al. 1999). We did not extinguish 
operant responding in this study but instead exposed rats to 13 days of forced abstinence 
in their home cage prior to our model of “relapse” behavior. This model of ethanol 
seeking behavior simulates aspects of alcohol relapse in humans as many people undergo 
forced periods of abstinence (e.g., hospitalization, incarceration) prior to being re-
exposed to alcohol-related cues that may precipitate relapse (reviewed in Reichel and 
Bevins 2009). Recently, alcohol craving was shown to increase over time during a 60-day 
period of forced abstinence in human alcoholics (Li et al. 2015). Future studies should 
investigate whether naltrexone reduces “relapse” lever pressing for ethanol following 
longer periods of forced abstinence and if naltrexone efficacy changes across an 
“incubation of craving” period. 
 An unexpected finding from our study is that age of onset of operant sweetened 
ethanol self-administration affected “relapse” behavior differently when tested in 
adulthood. Rats that began sweetened ethanol self-administration in adolescence pressed 
significantly fewer times in the “relapse” test of seeking behavior than rats that began in 
adulthood. Attenuated cue-induced reinstatement has previously been shown in 
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adolescent rats compared to adults following operant self-administration of cocaine, 
heroin and morphine (Doherty et al. 2009; Doherty and Frantz 2012; Li and Frantz 2009). 
Therefore, it is possible a common mechanism exists across drugs of abuse that leads to 
reduced “relapse” behavior in adulthood specific to onset of operant self-administration 
that begins in adolescence. Our previous work did not report age differences in “relapse” 
lever presses using a behavioral protocol that differed slightly from that used in the 
present study. In the previous work, the “relapse” test occurred without injections 
because we did not test whether any pharmacological agents would alter the behavior 
(Doherty and Gonzales 2015). Therefore, an alternative explanation for the age difference 
seen in the current work is the stress from injection may have affected the two age groups 
differently. However, adolescent drug or alcohol exposure has been shown to increase 
stress-induced reinstatement or consumption compared to adults (Siegmund et al. 2005; 
Wong and Marinelli 2016). As such, it is unlikely injection stress is the cause of reduced 
“relapse” behavior in the rats that began operant self-administration in adolescence. 
Additional work is needed to determine the possible mechanisms that underlie the age 
differences in relapse behavior we observed here. 
 A significant proportion of the adolescent rats had little or no detectable BEC on 
the test day (sessions 8-10) within the appetitive/consummatory phase of the experiment. 
We previously reported that following an intragastric challenge of 1 g/kg sweetened 
ethanol, adolescent rats showed significantly lower peak BEC, shorter time to BEC peak 
and a trend for faster elimination rate suggesting a larger volume of distribution and 
higher metabolism compared to adults (Doherty and Gonzales 2015). The ND adolescent 
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rats in the current study also consumed significantly less ethanol on BEC test day. 
Therefore, it is likely the nondetectable BECs may be attributed to the lower dose of 
ethanol consumed along with the aforementioned pharmacokinetic differences in 
adolescent rats. Despite ND adolescents consuming significantly less total ethanol prior 
to the PR test, these rats did not differ from adolescents with detectable BECs in PR and 
“relapse” tests. Together, these results suggest the ND adolescents experienced the 
central pharmacological effects of ethanol prior to the PR and “relapse” tests. One 
limitation to our interpretation is that BEC was only tested on one day across the 
experiment. Future studies are necessary to fully characterize the pharmacokinetics of 
operant sweetened ethanol self-administration throughout the entire period of 
adolescence to adulthood.   
Collectively, our results suggest naltrexone is effective at reducing ethanol 
consumption, motivation to obtain ethanol and “relapse” of lever pressing behavior in 
rats that began operant sweetened ethanol self-administration in adolescence or 
adulthood. Recent clinical research has demonstrated naltrexone can reduce heavy 
drinking and blunt craving in adolescents (ages 15-19) and young adults (ages 18-25), 
although larger trials are needed (Miranda et al. 2014; O’Malley et al. 2015). The current 
findings provide insight into consummatory, motivational and “relapse” behaviors that 
may be targeted by naltrexone in an adolescent animal model of moderate operant 
sweetened ethanol consumption, and highlight the need for continuing clinical 
investigation of efficacy in this population. Together, these results support the use of 
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opioid receptor antagonism as a potential mechanism for effective treatment for late 























Chapter 3: High sensitivity HPLC method for analysis of in vivo 
extracellular GABA using optimized fluorescence parameters for o-
phthalaldehyde (OPA)/sulfite derivatives 
 
ABSTRACT 
 Reversed-phase HPLC with derivatization using o-phthalaldehyde (OPA) and 
sulfite allows electrochemical detection of γ-aminobutyric acid (GABA) in microdialysis 
samples. However, OPA/sulfite derivatives have been reported to produce a lower 
fluorescent yield than other OPA/thiol derivatives. To overcome this limitation we 
examined excitation and emission spectra, reaction time, pH, and concentration of 
reagents in the derivatization solution. Optimal detection parameters were determined as 
λex=220 nm and λem=385 nm for maximal fluorescence. The derivatization reaction 
occurred immediately and the product was stable up to 10 minutes. A pH of 10.4 for the 
borate buffer used in the derivatization solution was significantly better than lower pH. 
Increasing the amount of sulfite combined with diluting the derivatization solution in 
borate buffer resulted in complete separation of the GABA peak from contaminants 
without any loss in signal. Controlling the temperature of the detector at 15°C 
significantly improved sensitivity with a detection limit of approximately 1 nM. To 
validate this assay, we performed microdialysis in the dorsal striatum and ventral 
tegmental area (VTA) of adult Long Evans rats. GABA concentrations in dialysates were 
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determined using external standards and standard additions, in order to further confirm 
interfering peaks were not present in biological samples. Within the dorsal striatum 
(n=4), basal GABA concentrations were 12.9±2.2 and 14.5±2.2 nM (external and 
additions, respectively). Respective basal GABA concentrations in the VTA (n=3) were 
4.6±1.1 and 5.1±0.6 nM. Thus, we have developed a novel, sensitive fluorescence 




















 γ-aminobutyric acid (GABA) is the primary amino acid neurotransmitter involved 
in inhibitory synaptic transmission and alterations in GABAergic signaling contribute to 
many neurological conditions including epilepsy, schizophrenia and anxiety disorders 
(Wong et al. 2003). Microdialysis is a technique commonly used in basic and clinical 
neuroscience to measure the concentration of GABA in the extracellular space (Chefer et 
al. 2009b; Shah et al. 2002). Many separation approaches exist for analysis of amino acid 
neurotransmitters, although high performance liquid chromatography (HPLC) remains 
one of the most widely used in neuroscience (Shah et al. 2002). However, GABA is 
neither fluorescent nor electroactive and requires a derivatization procedure prior to 
detection with these methods (Roth 1971; Shah et al. 2002). 
 One of the most well characterized derivatization reagents used for analysis of 
amino acid neurotransmitters is o-phthalaldehyde (OPA), which reacts with amines in the 
presence of a nucleophile to form electroactive and/or fluorescent isoindole derivatives 
(Chen et al. 1979; Lindroth and Mopper 1979; Roth 1971; Simons and Johnson 1978). 
The use of OPA in conjunction with thiols (e.g. 2-mercaptoethanol (MCE), 3-
mercaptopropionic acid (MPA)) has been widely used for both electrochemical (ECD) or 
fluorescence detection (FLD) of low concentrations of GABA in microdialysis samples 
(Bourdelais and Kalivas 1991; Donzanti and Yamamoto 1988; Durkin et al. 1988; 
Piepponen and Skujins 2001; Rea et al. 2005; Westerink and de Vries 1989; Zhang et al. 
2005). However, in addition to a pungent odor, thiol derivatives can be unstable (Lasley 
et al. 1984; Lindroth and Mopper 1979). This can be particularly problematic when 
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quantifying GABA in microdialysis samples due to highly specific chromatographic 
conditions required for separation (Rea et al. 2005).  
 An alternative to thiols is using OPA in the presence of a sulfite group as the 
nucleophile to form an N-alkyl-1-isoindole sulfonate derivative that has been reported to 
be more stable than thiol-formed derivatives (Jacobs 1987; Rowley et al. 1995). 
OPA/sulfite derivatization has been successfully used in multiple applications to measure 
GABA in brain microdialysates using ECD (Bongiovanni et al. 2001; Reinhoud et al. 
2013; Rowley et al. 1995; Smith and Sharp 1994). These ECD methods require high 
working potentials (0.7-0.85 V) for GABA detection and can result in more frequent 
maintenance of the electrochemical cell. In contrast, FLD offers advantages in ease of 
operation and stability over long periods of time. However, OPA/sulfite derivatives were 
reported to be significantly less fluorescent than OPA/thiol derivatives and not useful for 
high sensitivity analysis of GABA in microdialysis samples (Kehr 1993).  
 Previous studies using FLD quantified GABA in tissue or brain microdialysates 
using OPA/thiol derivatives reported ranges of 330-365 nm and 420-530 nm for 
excitation (λex) and emission (λem) wavelengths, respectively (deFreitas Silva et al. 2009; 
Kehr 1998; Peng et al. 2008; Vihavainen et al. 2008). Recently, excitation and emission 
spectra were thoroughly examined for amino acids derivatized with OPA/MPA, including 
GABA. These authors observed the maximal signal for the OPA/MPA derivative of 
GABA occurred at λex=229 nm and λem =450 nm, which resulted in a six-fold greater 
signal compared to previous wavelengths used (Perucho et al. 2015). Therefore, we 
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hypothesized the low fluorescence yield previously reported for OPA/sulfite derivatives 
may have been due to suboptimal detection parameters.  
 Thus, the aim of the present study was to develop a sensitive method for 
quantification of GABA in brain microdialysis samples using HPLC-FLD of an 
OPA/sulfite derivative. We determined optimal detection wavelengths, derivatization 
components, and reaction procedures for analysis of GABA. Additionally, we used in 
vivo microdialysis to quantify extracellular GABA in the dorsal striatum or ventral 
tegmental area (VTA) of Long Evans rats using external standards and standard additions 
to validate our method.  
 
MATERIALS AND METHODS 
Reagents 
 GABA, GABase from Pseudomonas fluorescens, OPA, sodium dihydrogen 
phosphate dihydrate, sodium sulfite and sodium tetraborate decahydrate were obtained 
from Sigma (Sigma-Aldrich, Saint Louis, MO, USA). Methanol was purchased from 
Fisher Scientific (Fisher Scientific, Fair Lawn, NJ, USA) and absolute ethanol from 
AAPER (AAPER Alcohol and Chemical Co., Shelbyville, KY, USA). Artificial cerebral 
spinal fluid (ACSF) for microdialysis experiments consisted of 149 mM NaCl, 2.8 mM 
KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.4 mM D-glucose. All solutions were made with 
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deionized water obtained from a Milli-Q system (Millipore, Billerica, MA, USA) and 
filtered using 0.2 μm nylon filters (Pall Corp., Ann Arbor, MI, USA). 
Instrumentation 
Liquid chromatography 
 HPLC separation was achieved using a Luna C18(2) column (150 x 1.0 mm, 3 
µm; Phenomenex, Torrance, CA, USA), Antec LC110 pump (Antec Leyden, 
Zoeterwoude, Netherlands), in-line degasser, column compartment (maintained at 40°C) 
equipped with a manual injector (9725i Rheodyne, Cotati, CA, USA) and 
polyetheretherketone (PEEK) 20 μl injection sample loop. Mobile phase was pumped at 
0.05-0.1 ml/min. Injection volume varied from 5 to 10 μl using Hamilton syringes (1702 
or 705, Hamilton Co., Reno, NV, USA).  
Mobile phase 
The mobile phase consisted of 0.1 M sodium dihydrogen phosphate dihydrate 
(NaH2PO4  2H2O) adjusted to pH 4.5 using 1 M phosphoric acid and 10-18% (v/v) 
methanol added to optimize chromatography. 
Fluorescence detection 
 Analyte detection was achieved using a Jasco FP-4020 fluorescence detector with 
a 12.7 μl analytical flow cell (Jasco Corp., Tokyo, Japan). The detector gain was set to 
1000, and the response time was 3 seconds. We attached a glass coverslip to the flow cell 
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to serve as an emission filter. Slit widths of 20 nm for excitation and 40 nm for emission 
were used.  
 Optimal wavelengths were determined by performing excitation and emission 
scans using the Jasco FP-4020. Differences in signal of the GABA derivatization product 
(1 μM) and the mobile phase were calculated for corresponding scans. Scans were 
triggered manually after the peak passed a threshold point of half the total signal of the 
GABA peak, and were taken at a scan speed of 200 nm/sec. Scans were performed at a 
gain set at 100 to ensure outputs were on scale. 
 Chromeleon 6.8 Chromatography Data System software (Thermo Fisher 
Scientific, Waltham, MA, USA) was used for data acquisition and analysis. All 
experiments were run at minimum in triplicate across days. Chromatographic peaks were 
required to have a signal to background noise ratio of at least 3:1 for analysis. 
Derivatization procedure 
 The derivatization working solution was made by dissolving 11 mg o-
phthaldialdehyde (OPA) in 250 μl absolute ethanol, 250 μl 1 M sodium sulfite (sulfite; 
Na2SO3) and 4.5 ml 0.1 M sodium tetraborate decahydrate (borate; Na2B4O7  10H2O; 
adjusted to pH 10.4 with 5 M NaOH) according to the methods of Smith and Sharp 
(Smith and Sharp 1994). During the optimization experiments, final volumes of sulfite 
and borate buffer used in working solution were adjusted to improve chromatography 
(detailed in Section 3.3). The sulfite solution was made every 2 days and the borate 
solution made every 7 days to achieve optimal signal. Both solutions were stored in glass 
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at room temperature. The OPA/sulfite working solution was stored in covered plastic 
vials at 4°C up to 24 hours. Stock GABA standards were prepared by dissolving GABA 
in deionized water at a concentration of 1 mM and stored at 4°C for up to 1 month. 
Standard dilutions were made fresh daily in either water or borate buffer based on the 
experiment. Polypropylene centrifuge tubes were used for standard and sample tubes to 
reduce loss of GABA by adsorption (Boyd and Kennedy 1998; Rowley et al. 1995). 
 The derivatization procedure consisted of combining 9 μl of GABA standard or 
sample with 2 μl borate and then adding 0.5 μl OPA working solution. The additional 
borate added to the reaction mixture was used due to more reproducible separation. This 
reaction mixture was manually mixed with a pipette and incubated at room temperature 
in darkness.  
In vivo microdialysis procedures 
 Adult, male Long Evans rats (n=7; 290-301 g upon arrival; Charles River 
Laboratories, Raleigh, NC, USA) were surgically implanted with a 21 gauge guide 
cannula (Plastics One, Roanoke, VA, USA) above the dorsal striatum (in mm relative to 
bregma and skull surface: 0.0 antero-posterior, +3.7 lateral, -3.0 ventral) or VTA (-5.8 
antero-posterior, +2.1 lateral, -4.6 ventral, angled 10° toward midline) using procedures 
similar to our previous studies (Doyon et al. 2005). The dorsoventral coordinate 
represents the bottom of the guide cannula, and the probes for either brain region extend 
4.0 mm below the cannula when seated into the guide. Animals were allowed at least 5 
days of recovery prior to microdialysis experiments.  
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 Microdialysis probes (length of probe active area: dorsal striatum 3 mm, VTA 1 
mm; 13,000 molecular weight cutoff) were constructed similar to Pettit and Justice (Pettit 
and Justice 1991a) and implanted 12-18 hours prior to experiments. Probes were perfused 
with ACSF at 0.2 µl/min flow rate overnight, and then increased to 1.0 (VTA) or 2.0 
µl/min (dorsal striatum) at least two hours prior to dialysis sampling. Microdialysis 
sampling occurred during 0800 – 1600, during the light cycle of the animals. Dialysis 
samples were immediately frozen on dry ice and stored at -80ºC until analysis. 
Microdialysis probe placements were confirmed via histological analysis. All animal 
procedures complied with the National Institutes of Health Guide for Care and Use of 
Laboratory Animals (8th Ed., 2011) and were approved by the Institutional Animal Care 
and Use Committee of the University of Texas at Austin. 
Standard additions 
 Basal dialysates were pooled for each rat. Each pooled sample was analyzed in 
triplicate. Pooled dialysates from dorsal striatum were diluted 1:1 in borate prior to 
derivatization to reduce large peaks of biological origin present in the samples. The first 
injection used 9 μl of the diluted dialysate sample mixed with 2 μl borate and 0.5 μl of 
the optimal OPA working solution determined in Section 3.3. The two remaining 
injections substituted the 2 μl borate in the derivatization with an equal volume of GABA 
standard made in borate. GABA concentration used in standard additions varied based on 
brain region (dorsal striatum: 25, 50 nM; VTA: 10, 25 nM). Basal values are not 




 GABA signals in optimization experiments were analyzed using analysis of 
variance (ANOVA) or t-tests. Basal GABA concentrations calculated using external 
standards and standard additions were compared using paired t-tests. Bonferroni’s post 
hoc comparisons were used as appropriate, and results with p<0.05 were assigned 
significance; ns=not significant. Data were analyzed using GraphPad Prism 6.0 software 
(GraphPad Software, La Jolla, CA, USA).  
 
RESULTS AND DISCUSSION 
Optimization of excitation and emission wavelengths 
 The fluorescence of thiol-substituted isoindoles has a range of reported excitation 
and emission wavelengths used for detection of OPA derivatives of GABA (Perucho et 
al. 2015). Using a 5-minute precolumn reaction time and the derivatization solution 
described in Section 2.3, we initially compared excitation and emission conditions similar 
to previous reports using OPA/MCE or MPA derivatives (λex=330 nm, λem=450 nm) (Rea 
et al. 2005; de Freitas Silva et al. 2009) with conditions recently described to be more 
sensitive for OPA/MPA GABA derivatives (λex=240, λem=450 nm) (Perucho et al. 2015). 
We observed a significant increase in GABA signal at 240 nm for the excitation 
wavelength (data not shown). Following a series of manual adjustments, we performed 
the excitation spectrum scan between 200 and 360 nm with the emission set at 400 nm. 
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The peak of maximal intensity was λex=220 nm, with another significantly smaller peak at 
330 nm. Then, we performed the emission spectrum scan between 330 and 600 nm with 
the excitation set at 220 nm. The peak of maximal intensity was λem=385 nm. Scans were 
repeated in triplicate using derivatization solution determined in Section 3.3 to confirm 
results. Optimal wavelengths to achieve the highest signal for an OPA/sulfite GABA 
derivative were determined to be excitation λmax=220 nm and emission λmax=385 nm (Fig. 
3.1). However, the emission wavelength was changed to 400 nm in order to optimize 
chromatography. We used λex=220 nm and λem=400 nm for experiments unless otherwise 
noted. 
Derivative stability 
 Initially using λex=229 nm and λem=425 nm for detection, the stability of the 
OPA/sulfite GABA derivative was tested by comparing the signal after different reaction 
times for the derivatization procedure up to 10 minutes. The zero time point was mixed 
and immediately manually injected into the system, which took approximately 30 
seconds total. We found no significant differences in signal achieved between time points 
up to 10 minutes (Fig. 3.2; F3,8=2.89, ns). Therefore, the GABA OPA/sulfite derivative 
appears to display maximal fluorescence immediately under our conditions. This is in 
contrast to Rowley et al. who reported maximal GABA signal at 5 minutes of an 
OPA/sulfite derivative using ECD (Rowley et al. 1995). Additional reaction times were 
not tested, therefore it is possible the derivative is stable longer than 10 minutes. The 
 
 59 
reaction was standardized to 1 minute in darkness prior to manual injection for all 
following experiments.  
Optimization of derivatization procedures 
Effect of pH 
 Derivatization conditions including reagent composition and ratio of OPA to the 
nucleophile additive are well documented to significantly influence chromatography for 
other thiols reviewed in (Molnár-Perl and Bozor 1998). In order to determine the optimal 
OPA/sulfite derivatization conditions using fluorescence detection (λex=229 nm and 
λem=425 nm), we first examined the effect of pH of borate buffer (8.4, 9.4, 10.4) on the 
GABA derivative signal. For each pH tested, the borate buffer solution used in the OPA 
derivatization working solution was made in triplicate. There was a significant difference 
in GABA signal detected between pH of borate buffers tested (F2,6=471.2, p<0.001). Post 
hoc analyses revealed no significant differences between pH 10.4 and 9.4, however at pH 
8.4 the GABA signal was significantly lower (Fig. 3.3; p<0.001). Therefore, for all 
additional experiments the pH of the borate buffer used was adjusted to 10.4.  
 The stock derivatization working solution was made by dissolving 11 mg OPA in 
250 μl absolute ethanol, 250 μl 1 M sulfite and 4.5 ml 0.1 M borate based on procedures 
reported for electrochemical detection of OPA/sulfite derivatives (Smith and Sharp 
1994). Using this working solution, another peak following GABA sometimes interfered 
with quantification of GABA concentration. Adjusting the methanol concentration in the 
mobile phase improved separation of GABA from this unknown peak (data not shown), 
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however relying on these adjustments alone reduced reproducibility over time due to the 
extreme sensitivity of GABA to methanol (Rea et al. 2005). As a result, we sought to 
optimize the derivatization working solution to minimize excess OPA and therefore 
reduce other derivative products leading to an improvement in the separation of the 
GABA peak.  
Effect of OPA:sulfite ratio 
 We first investigated how the mole ratio of OPA to sulfite in the derivatization 
solution would influence chromatography. The mole ratio in the stock derivatization 
solution was 1 OPA to 3 sulfite (1 O: 3 S) as originally reported by Smith and Sharp 
(Smith and Sharp 1994). We increased the amount of sulfite in the derivatization so the 
mole ratio was 1 OPA to 10 sulfite (1 O: 10 S; high sulfite) to test whether this 
modification would reduce the peak following GABA in the chromatogram (λex=229 nm 
and λem=425 nm). This high sulfite derivatization solution was made by dissolving 11 mg 
o-phthaldialdehyde (OPA) in 250 μl absolute ethanol, 820 μl 1 M sulfite and 3.93 ml 0.1 
M borate. Both OPA solutions were also diluted 1:10 in borate in an effort to reduce 
additional peaks in the chromatogram. There was no significant difference in GABA 
signals observed using the various derivatization solutions (Fig. 3.4; F3,8=0.80, ns) and 




Effect of OPA concentration 
 We next investigated whether diluting the OPA working solution with borate 
buffer would improve chromatography (λex=229 nm and λem=425 nm). We initially 
compared the stock derivatization working solution with 1:10, 1:30 and 1:100 dilutions in 
borate and observed a significant difference in signal (F3,8=24.97, p<0.001). Post hoc 
comparisons showed only the 1:100 dilution resulted in a significantly lower GABA 
signal (Fig. 3.5A; p<0.01). The other dilutions in borate (1:10 and 1:30) no had effect on 
GABA signal but did reduce additional peaks in the chromatogram. Using the high sulfite 
derivatization working solution shown to optimize separation in Figure 4, we tested 
whether further borate dilution of this solution would improve chromatography now 
using λex=220 nm and λem=400 nm for detection. Dilutions of the high sulfite 
derivatization solution in borate resulted in optimal GABA separation with no reduction 
in signal (Fig. 3.5B; t(10)=0.45, ns). The reduction in additional peaks and improvement 
in GABA separation between using the original OPA derivatization solution and the OPA 
solution with higher sulfite diluted in borate buffer is illustrated in Figure 3.6. 
 Our results show the derivatization protocol determined to optimize GABA 
sensitivity and resolution was prepared by dissolving 11 mg OPA in 250 μl absolute 
ethanol, 820 μl 1 M sulfite and 3.93 ml 0.1 M borate, then diluting this OPA working 
solution 1:20 (v/v) in borate. This derivatization solution was used to further determine 
method sensitivity and quantify GABA concentration in microdialysis samples using 
λex=220 nm and λem=400 nm as detection wavelengths. 
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Effect of temperature on fluorescence 
 Increases in temperature can reduce fluorescence intensity (Bowen and West 
1955; Suzuki et al. 1977), which can occur by changes in ambient room temperature or 
directly from equipment. We tested the sensitivity of our method with no temperature 
control and using the FLD to maintain temperature at 15°C. The temperature of the 
column compartment was 40°C for both conditions. When FLD temperature was 
controlled at 15°C, there was a significant increase in slope of the standard calibration 
curve (6.25 – 25 nM GABA) reflecting an improvement in the sensitivity of our method 
(Fig. 3.7; F1,20=36.26, p<0.001). We further confirmed the increase in sensitivity using 
standard calibration curves with low concentration GABA standards (1.5 – 12.5 nM). A 
detection limit of 1 nM was calculated from the average of triplicate calibration curves as 
the concentration resulting in a signal 3 times the peak-to-peak noise of the baseline from 
the average of triplicate OPA derivative blanks. 
In vivo validation using standard additions 
 Reported extracellular GABA concentrations from rodent microdialysis studies 
vary substantially both between and within different brain regions (Fliegel et al. 2013). 
Methodology used in the microdialysis experiments likely contributes to these 
differences, however chromatographic conditions are also a factor as other peaks of 
biological origin can interfere with accurate GABA quantification (Rea et al. 2005). We 
applied our method to quantify basal extracellular GABA from microdialysis samples in 
dorsal striatum and VTA of Long Evans rats. In order to examine whether other peaks 
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were interfering with the GABA peak in dialysate samples, we used both external 
standards and standard additions to determine GABA concentrations. Calibration curves 
from standard additions to pooled dialysate samples displayed good linearity (Fig. 3.8; 
dorsal striatum R2=0.97, VTA R2=1.00). The GABA concentration in samples calculated 
using external standards was compared to concentration determined from standard 
additions (x-intercept of the regression) for each rat individually. Average GABA 
concentrations are shown in Table 3.1. There were no significant differences between 
basal concentrations calculated using external standards compared to standard additions 
for either brain region (dorsal striatum: t(3)=2.22, ns; VTA: t(2)=0.91, ns). Our results 
confirm additional peaks of biological origin are not present underneath the GABA peak. 
In addition, we further validated the identity of the GABA peak qualitatively using 
enzyme degradation with GABase from Pseudomonas fluorescens in both standards and 
dialysate samples (data not shown).  
 
Table 3.1  Basal GABA concentrations calculated using external GABA standards and 
standard additions  
Dorsal striatum (n=4) and ventral tegmental area (VTA; n=3). Values for dorsal striatum 
corrected for dilution factor in borate. Basal values are not corrected for probe recovery. 
Data are presented as mean ± sem.  
Brain region External standards Standard additions 
Dorsal striatum 12.9 ± 2.2 nM 14.5 ± 2.2 nM 




Figure 3.1  Maximal excitation and emission spectra for OPA/sulfite GABA derivative 
The difference in signal of the GABA derivatization product and the mobile phase was 
calculated for each scan and data are presented as mean of three separate scans. Emission 
wavelength set to 400 nm for excitation scan. Excitation wavelength set to 220 nm for 




























Figure 3.2  Stability of the OPA/sulfite GABA derivative up to 10 minutes  
Maximum fluorescence of the derivative is immediate and stable up to 10 minutes. Data 






























Figure 3.3  Effects of borate buffer pH in derivatization working solution on GABA 
signal 
A pH of 8.4 significantly reduces fluorescence of the OPA/sulfite GABA derivative (*** 


























Figure 3.4  Effects of adjusting the ratio of OPA to sulfite in the derivatization solution 
on GABA signal 
Increasing sulfite in OPA solution improved separation of GABA with no significant 
reduction in GABA signal. Original OPA derivatization solution consisted of a mole ratio 
of 1 OPA: 3 sulfite. High sulfite derivatization solution consisted of a mole ratio of 1 
OPA: 10 sulfite. Signals from stock and 1:10 dilutions in borate were compared for each 
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Figure 3.5  Effects of diluting the original derivatization working solution (A) or high 
sulfite derivatization working solution (B) in borate on GABA signal 
(A) Maximal GABA signal was maintained at 1:10 or 1:30 dilution in borate while 
reducing additional peaks compared to stock solution. A 1:100 dilution of the 
derivatization working solution in borate significantly reduced the GABA signal (** 
indicates p<0.01). (B) Using a high sulfite derivatization working solution, no effects on 
GABA signal were observed between 1:10 and 1:20 dilution in borate. For both panels 
data are presented as mean ± sem.  






































Figure 3.6  Representative chromatograms showing improved GABA peak separation 
by optimizing the derivatization working solution 
Optimization of OPA reagent eliminated co-eluting peaks without reducing GABA 
signal. Dotted lines represent OPA blanks and solid lines represent GABA standard (500 
nM) injections, arrows indicate GABA peak. Original OPA derivatization solution [mole 
ratio 1 OPA: 3 sulfite] (A) compared to high sulfite OPA derivatization solution [mole 
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Figure 3.7  Effect of temperature on fluorescence of OPA/sulfite GABA derivative  
Controlling the temperature of the detector at 15°C significantly increased GABA signal 

































Figure 3.8  Method of standard additions using in vivo dialysates from dorsal striatum 
and ventral tegmental area of Long Evans rats 
Dorsal striatum (R2=0.97, n=4); ventral tegmental area (VTA: R2=1.00, n=3). Values not 






























We have determined excitation and emission wavelengths that allow for a novel, 
sensitive fluorescence method to detect GABA using HPLC of an OPA/sulfite derivative. 
The derivatization solutions and procedure were optimized to achieve reliable GABA 
peak separation in brain microdialysis samples. We validated our method by quantifying 
extracellular GABA using external standards and standard additions, further confirming 
no interfering peaks were present in biological samples. The described method is 
advantageous for various neuroscience applications that require sensitive, reliable 













Chapter 4: Local GABA uptake inhibition reduces in vivo extraction 
fraction in the ventral tegmental area of Long Evans rats measured by 
quantitative microdialysis under transient conditions 
 
ABSTRACT 
 Inhibitory signaling in the ventral tegmental area (VTA) is involved in the 
mechanism of action for many drugs of abuse. Although drugs of abuse have been shown 
to alter extracellular γ-aminobutyric acid (GABA) concentration in the VTA, knowledge 
on how uptake mechanisms are regulated in vivo is limited. Quantitative (no net flux) 
microdialysis is commonly used to examine the extracellular concentration and clearance 
of monoamine neurotransmitters, however it is unclear whether this method can be used 
to estimate clearance for amino acid neurotransmitters such as GABA. The purpose of 
this study was to determine whether changes in GABA uptake are reflected by in vivo 
extraction fraction within the VTA. Using quantitative (no net flux) microdialysis 
adapted for transient conditions, we examined the effects of local perfusion with the 
GABA uptake inhibitor, nipecotic acid, in the VTA of Long Evans rats. Basal 
extracellular GABA concentration and in vivo extraction fraction were 44.4 ± 1.9 nM and 
0.19 ± 0.01, respectively. At maximal effect, nipecotic acid (50 μM) significantly 
increased extracellular GABA concentration to 170 ± 4.1 nM and reduced in vivo 
extraction fraction to 0.11 ± 0.003. Extraction fraction returned to baseline immediately 
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following removal of nipecotic acid from the perfusate. Due to reduced in vivo extraction 
fraction, conventional microdialysis substantially underestimated the increase of 
extracellular GABA from local uptake inhibition by nipecotic acid perfusion. Together, 
these results suggest inhibiting GABA uptake mechanisms within the VTA alters in vivo 





















 The ventral tegmental area (VTA) is a brain region involved in reward processing, 
aversion and the development of some drug-dependent behaviors (Fields et al. 2007; 
Lüscher and Malenka 2011; Oliva and Wanat 2016). Inhibitory signaling in the VTA is 
altered by many drugs of abuse and γ-aminobutyric acid (GABA) neurons have an 
emerging role in regulating reward and aversive learning (Bocklisch et al. 2013; Creed et 
al. 2014; Nugent and Kauer 2008). Despite the importance of inhibitory signaling in the 
VTA for drug-related behaviors, little is known how extracellular GABA concentration in 
the VTA is regulated. 
 GABA transporters (GATs) on neurons and astrocytes are critical in the 
regulation of GABA in the extracellular space (Scimemi 2014). Within the central 
nervous system, GAT-1 is the primary neuronal isoform and GAT-3 is strongly expressed 
in astrocytes (Borden 1996; Roth and Draguhn 2012). Inhibition of GATs reduces GABA 
uptake from the synaptic cleft and is a useful drug target for the treatment of epilepsy, 
pain and anxiety (Bröer and Gether 2012). Tiagabine, a highly selective GAT-1 inhibitor, 
is currently approved as an adjunctive treatment for partial epilepsy (Meldrum and 
Rogawski 2007). There is also clinical evidence that tiagabine may be effective in 
decreasing drug taking behavior, craving and withdrawal signs (González et al. 2007; 
Myrick et al. 2005; Sofuoglu et al. 2005). More recently, animal studies have shown that 
GATs can contribute to changes in GABAergic signaling during drug withdrawal 
(Bagley et al. 2011), and midbrain dopamine neurons also express GATs to facilitate co-
release of GABA (Tritsch et al. 2014). Together, these results suggest the maintenance of 
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drug-related behaviors may involve changes in the regulation of extracellular GABA 
concentration in certain brain regions. 
 Microdialysis is one technique used to study the regulation of GABA 
concentration in the extracellular space. Dialysate GABA concentrations are interpreted 
as an index of volume transmission from the interaction between neurons and astrocyte 
networks rather than a fast measure of synaptic release (Del Arco et al. 2003; Nyitrai et 
al. 2006). However, the mechanisms of regulation of extracellular GABA in the VTA are 
not clear, in part due to low reported basal concentrations and specific chromatographic 
conditions required for accurate quantification (Fliegel et al. 2013; Rea et al. 2005). 
Despite these challenges, several studies have measured changes in dialysate GABA 
concentration within the VTA in response to acute or chronic treatment with drugs of 
abuse (Bankson and Yamamoto 2004; Buczynski et al. 2016; Klitenick et al. 1992; 
Natividad et al. 2012; O’Dell and Parsons 2004; Sotomayor-Zarate et al. 2015; 
Vihavainen et al. 2008). However, dialysate measurements may not accurately reflect 
changes in extracellular concentration due to the independent influence of in vivo 
extraction fraction, which can be altered by neurotransmitter clearance (Parsons et al. 
1991). The high efficiency of GABA clearance by GATs maintains low extracellular 
concentrations and may interfere with accurate determination of effects on neuronal 
release following drug administration. Therefore, while previous work implicates 
changes in extracellular VTA GABA concentration in the mechanism of many drugs of 
abuse, it is critical to examine the influence of uptake when interpreting changes in 
dialysate GABA levels. 
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  In contrast to conventional microdialysis, quantitative (no net flux) microdialysis 
is a technique that involves including different concentrations of the analyte sequentially 
within the perfusate in order to determine the point of “no net flux” across the probe 
membrane, indicating the actual extracellular concentration in the brain at steady state 
conditions (Justice 1993; Lonnroth et al. 1987). The in vivo extraction fraction, or relative 
recovery of the probe, is the slope of the regression line determined from the experiment 
and has been shown to be an estimate of neurotransmitter clearance for monoamines and 
acetylcholine (Parsons and Justice 1992; Smith and Justice 1994; Cosford et al. 1996; 
Vinson and Justice 1997). It is less clear whether in vivo extraction fraction estimates 
clearance for amino acid neurotransmitters that are regulated by both neurons and 
astrocytes. For glutamate, reduced in vivo extraction fraction coincided with lower 
protein expression of excitatory amino acid transporter 1 (EAAT1) in the VTA (Ding et 
al. 2013). However, it is currently unknown whether changes in GABA uptake are 
reflected by changes in microdialysis in vivo extraction fraction.  
 GABA clearance from the extracellular space is primarily mediated through 
uptake by transporters, therefore we hypothesized that inhibiting GATs would 
significantly reduce the in vivo extraction fraction measured using microdialysis. We 
used a modification of quantitative microdialysis under transient conditions (Olson and 
Justice 1993) to measure the direct effects of nipecotic acid, a GAT inhibitor, on 
extracellular GABA concentration and in vivo extraction fraction over time in the VTA of 






 Adult, male Long Evans rats (n=32; Harlan, Indianapolis, IN) were maintained in 
a humidity and temperature controlled room with a 12-hour light/dark cycle (lights on at 
0700). Animals were pair housed and handled daily for at least one week to acclimate to 
facility prior to surgery. Food and water were available ad libitum. All animal procedures 
complied with the National Institutes of Health Guide for Care and Use of Laboratory 
Animals (8th Ed., 2011) and were approved by the Institutional Animal Care and Use 
Committee of the University of Texas at Austin. 
Materials 
 Nipecotic acid, GABA, o-phthalaldehyde (OPA), sodium dihydrogen phosphate 
dihydrate, sodium sulfite and sodium tetraborate decahydrate were purchased from Sigma 
(Sigma-Aldrich, Saint Louis, MO). Methanol from Fisher Scientific (Fisher Scientific, 
Fair Lawn, NJ) and absolute ethanol from AAPER (AAPER Alcohol and Chemical Co., 
Shelbyville, KY) were used. All solutions were made with deionized water from a Milli-
Q system (Millipore, Billerica, MA) and filtered using 0.2 μm nylon filters (Pall Corp., 
Ann Arbor, MI). Gentamicin (APP Pharmaceuticals, Schaumburg, IL) and carprofen 
(Pfizer, New York, NY) were used in surgery. Nipecotic acid and GABA were dissolved 




 Rats were anesthetized with isoflurane (5% induction, 2.5% maintenance) and 
guide cannulae (21 gauge, Plastics One, Roanoke, VA) were stereotaxically implanted 
above the VTA (mm relative to bregma and skull surface: anteroposterior -5.8, 
mediolateral +2.1, ventral -4.6 at 10° angle toward midline) according to atlas of Paxinos 
and Watson (2007). Probes extended 4.0 mm below the end of cannula when implanted 
for experiments. An obturator was placed in the guide cannula until probe implantation. 
Carprofen (5 mg/kg, subcutaneous) was given during surgery to minimize post-operative 
pain and discomfort. After surgery, rats were housed individually and underwent a 
recovery period of at least 5 days prior to microdialysis experiments. 
Microdialysis procedures 
 Microdialysis probes (1 mm active area, 13 kDa molecular weight cutoff) were 
constructed similar to Pettit and Justice (1991b), and experimental conditions were 
described previously (Doyon et al. 2003; Valenta et al. 2013). Rats (328-495 g on 
experiment day) were lightly anesthetized and probes inserted into cannula 12-18 hours 
prior to experiments. Probes were perfused with ACSF (149 mM NaCl, 2.8 mM KCl, 1.2 
mM CaCl2, 1.2 mM MgCl2, 5.4 mM D-glucose) at 0.2 μl/min overnight and then the flow 
rate was increased to 1.0 μl/min at least two hours prior to the start of microdialysis 
experiments. Following this equilibration period, samples were collected every 20 
minutes and all experiments occurred between 0700 – 1700 hours, during the light phase 




 We first conducted an experiment to determine the concentration of the GABA 
uptake inhibitor nipecotic acid to perfuse through the probe for the quantitative 
microdialysis experiment. Following a baseline period, the probe perfusate (ACSF) was 
manually changed to a syringe containing nipecotic acid in ACSF (30, 100, 300 μM) in 
sequential order. Each nipecotic acid concentration was perfused for 60 minutes. After 
the final nipecotic acid concentration, the perfusate was changed back to ACSF for three 
additional samples. In control animals, the syringe was changed to a different syringe 
containing only ACSF with no inhibitor at each time point. The range of concentrations 
tested for nipecotic acid was chosen based on previous reports (Rea et al. 2005; 
Vihavainen et al. 2008). 
Experiment 2 
 A modification of the quantitative microdialysis (no net flux) adapted for transient 
conditions was used to determine the effects of local uptake inhibition on extracellular 
GABA concentration and in vivo extraction fraction (Lonnroth et al. 1987; Olson and 
Justice 1993). Probes were perfused with ACSF overnight as described above. The 
morning of the experiment, the perfusate was changed to ACSF including one of four 
GABA concentrations (0, 15, 45, 90 nM) and the flow rate increased to 1.0 μl/min for at 
least two hours. These GABA concentrations were chosen based on preliminary no net 
flux experiments (data not shown). After four baseline samples, the perfusate was 
manually changed to ACSF containing the same GABA concentration and nipecotic acid 
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(50 μM) for five samples, then returned to the baseline ACSF solution for four samples. 
Dialysis samples were immediately frozen on dry ice and stored at -80°C until analysis. 
GABA analysis 
 All samples underwent precolumn derivatization prior to analysis. The 
derivatization solution was based on previous reported methods (Rowley et al. 1995; 
Smith and Sharp 1994). The working solution was made by dissolving 11 mg OPA in 250 
μl absolute ethanol, 250 μl sodium sulfite (1 M) and 4.5 ml sodium tetraborate 
decahydrate (0.1 M, adjusted to pH 10.4 with 5 M NaOH; borate). The working solution 
was stored in a covered vial at 4°C. The derivatization procedure consisted of combining 
9 μl standard or sample with 2 μl borate then adding 0.5 μl OPA working solution, which 
was manually mixed and incubated in darkness at room temperature for 10 minutes. 
Stock GABA standards were prepared in deionized water and stored at 4°C for up to one 
month. Serial dilutions were prepared fresh daily. 
 The GABA concentration in samples was determined using high performance 
liquid chromatography with electrochemical detection. All samples were run with 
external standards. For the quantitative microdialysis experiment, GABA concentration 
in the ACSF perfusate for each rat was validated using external standards. Samples were 
run using a 9725i manual injector (Rheodyne, Cotati, CA), Luna C18(2) column (150 x 
2.0 mm, 3 μm; Phenomenex, Torrance, CA), Decade controller (column temperature 40-
45°C; Antec Leyden, Zoeterwoude, Netherlands) and 2 mm glassy carbon working 
electrode (SenCell or VT-03 with salt bridge Ag/AgCl reference; Antec) at +700 mV 
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potential. Aqueous mobile phase consisted of 0.1 M sodium dihydrogren phosphate 
dihydrate and 0.5 mM EDTA adjusted to pH 4.50 with 1 M phosphoric acid. Methanol 
was added (27% v/v) to mobile phase and sparged with helium prior to being pumped at a 
flow rate of 0.14-0.25 ml/min through the system. Following precolumn derivatization, 5-
10 μl of the reaction mixture was manually injected into the system. Chromeleon 6.8 
Chromatography Data System Software (Thermo Fisher Scientific, Waltham, MA) was 
used for chromatogram acquisition and peak integration. Chromatographic peaks were 
required to have a signal to background noise ratio of at least 2:1 in Experiment 1 and 3:1 
in Experiment 2 to be included in the analyses. 
Histological analysis 
 After microdialysis experiments, animals were administered a lethal dose of 
sodium pentobarbital (150 mg/kg, intraperitoneal) under isoflurane anesthesia. Brains 
were extracted and stored in 10% formalin. Coronal sections (120 μm) were stained with 
cresyl violet for probe verification (Paxinos and Watson 2007). Site of probe 
implantation was determined prior to data analysis. The probe active area was required to 





 Microdialysis data were expressed as percent of baseline from the average of the 
first three samples and analyzed using repeated measures ANOVA with perfusate 
treatment as a between-subjects factor and time as a repeated measure.  
Experiment 2 
 Quantitative microdialysis data were analyzed according to procedures described 
in Yim and Gonzales (2000). There were four subgroups (each subgroup, n=5-7) based 
on the concentration of GABA (0, 15, 45, 90 nM) in the perfusate during the experiment. 
Data from subgroups were used to create a linear regression for each time point by 
plotting [GABA]in-[GABA]out, the difference between the concentration perfused through 
the probe ([GABA]in) and the concentration in the sample ([GABA]out) compared with 
[GABA]in (Olson and Justice 1993). Linear regression was performed for each time point 
to calculate the extracellular GABA concentration (x-intercept) and in vivo extraction 
fraction (slope). The asymptotic standard errors for regression parameters were 
determined from the linear regression. The method of extra sum of squares was used to 
test if there were differences between regression lines (Kenakin 1997). If significant 
differences between regression lines were observed, additional F tests were carried out to 




 For all analyses, Bonferroni’s post hoc comparisons were used as appropriate. 
Values are reported as mean ± sem and results with p<0.05 were assigned significance. 
Data analysis was performed using GraphPad Prism (version 6; La Jolla, CA) or SPSS 




 The probe locations were verified as shown in Fig. 4.1, and ranged from 
approximately 5.28 to 6.36 mm posterior from bregma according to Paxinos and Watson 
(2007). In the quantitative microdialysis experiment (Fig. 4.1B), 87% of probe 
placements were located in the posterior VTA (defined as -5.6 to -6.3 mm from bregma) 
(Sanchez-Catalan et al. 2014). 
Experiment 1: Dose dependent effects of local uptake inhibition on GABA release 
using conventional microdialysis 
 In order to determine the concentration of nipecotic acid to use for the 
quantitative microdialysis experiment, we first tested the effects of three different 
concentrations (30, 100, 300 μM) of nipecotic acid, a GABA uptake inhibitor, on VTA 
GABA dialysate concentration using local application through the microdialysis probe. A 
control group of animals received only ACSF throughout the experiment but manual 
syringe changes occurred at same times as the group that received increasing 
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concentrations of nipecotic acid in the perfusate. The overall ANOVA revealed a 
significant interaction between treatment group and time (F14,84=40.7, p<0.0001). There 
was a significant difference over time in VTA GABA concentration as a percent of 
baseline in the group that received local nipecotic acid application (Fig. 4.2; F14,42=47.15, 
p<0.0001; n=4). Post hoc analyses revealed GABA concentration significantly increased 
due to nipecotic acid treatment between 140 – 240 minutes compared to controls (all 
p<0.001). Additionally, the GABA concentration in the first ACSF sample following the 
final nipecotic acid concentration (300 μM) was significantly elevated compared to 
controls (260 min, p<0.05). In contrast, GABA concentration did not significantly change 
over time in control animals as a result of manual ACSF syringe changes (F14,42=0.69, ns; 
n=4). 
Experiment 2: Effect of local uptake inhibition on extracellular GABA and in vivo 
extraction fraction using quantitative microdialysis under transient conditions 
 The results of Experiment 1 indicated a concentration higher than 30 μM 
nipecotic acid was necessary to significantly increase VTA GABA over baseline. 
Therefore, we tested the effect of 50 μM nipecotic acid delivered through the probe on 
extracellular GABA and in vivo extraction fraction in the VTA using quantitative 
microdialysis under transient conditions (Olson and Justice 1993). A separate group of 
animals was used for each GABA concentration in the ACSF perfusate (GABA (nM): 0, 
n=6; 15, n=5; 45, n=7; 90, n=6).  
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 The extracellular concentration of GABA and in vivo extraction fraction were 
calculated using linear regression, as illustrated by selected time points in Fig. 4.3. A 
positive value on the y-axis indicates net diffusion of GABA into the brain and a negative 
number indicates net GABA diffusion from the brain into the perfusate (Parsons and 
Justice 1992). The time course of extracellular GABA concentrations and in vivo 
extraction fraction are presented in Fig. 4.4. Analysis of the regression parameters 
between the four baseline time points revealed no significant differences (Fig. 4.3A; 
F6,8=0.88, ns). The average extracellular GABA concentration in the VTA and in vivo 
extraction fraction during the baseline were 44.4 ± 1.9 nM and 0.19 ± 0.01, respectively. 
 During the nipecotic acid perfusion, there was a significant difference observed in 
the regression line at each time point 100 – 180 minutes compared to baseline regressions 
(100 min, F8,10=17.9; 120 min, F8,10=25.6; 140 min, F8,10=106.3; 160 min, F8,10=89.5; 180 
min, F8,10=173.7; all p<0.001). Local nipecotic acid application significantly increased the 
extracellular GABA concentration (x-intercept) over baseline samples (Fig. 4.4; 100 min, 
F4,10=35.7; 120 min, F4,10=46.5; 140 min, F4,10=174.2; 160 min, F4,10=141.6; 180 min, 
F4,10=257.6; all p<0.001). In addition to the significant increase in extracellular GABA, 
nipecotic acid also significantly reduced the in vivo extraction fraction (slope) in most 
samples during the perfusion (Fig. 4.4; 100 min, F4,10=3.76; 140 min, F4,10=5.34; 160 min, 
F4,10=5.90; 180 min, F4,10=13.28; 100, 140 – 160 min p<0.05, 180 min p<0.01). Both 
effects were maximal following 100 minutes of nipecotic acid perfusion. At this time 
point (180 min), extracellular GABA concentration increased to 170 ± 4.1 nM and in vivo 
extraction fraction had fallen by approximately 40% (0.11 ± 0.003). 
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 After 100 minutes of nipecotic acid perfusion, the syringes were changed back to 
the original ACSF solution. There was a significant difference between the baseline 
regressions and the regression at the first time point following the nipecotic acid 
perfusion (200 min, F8,10=9.73, p<0.001). At this time point (200 min), the extracellular 
GABA concentration (x-intercept) was still significantly elevated (F4,10=19.1; p<0.001) 
but the in vivo recovery (slope) had returned to baseline (F4,10=0.72; ns). There were no 
significant differences between the four baseline regressions and the last 60 minutes of 
the experiment (Fig. 4.4; 220 min, F8,20=0.91, ns; 240 min, F8,20=0.84, ns; 260 min, 
F8,20=0.59; ns). The average extracellular GABA concentration and in vivo extraction 
fraction did not differ between baseline periods before and after the nipecotic acid 
perfusion (x-intercept: t(5)=1.21, ns; slope: t(5)=0.39, ns). 
 Figure 4.5 compares the time course of nipecotic acid perfusion on [GABA]out 
from the group that received 0 nM GABA in the perfusate to the extracellular GABA 
concentration determined from quantitative microdialysis as percent of baseline from the 
average of the four baseline time points. At the maximal effect, [GABA]out increased to 
230% of baseline while the extracellular concentration increased to almost 400% of 
baseline. Therefore, our results indicate conventional microdialysis underestimates the 
increase in extracellular GABA concentration measured following uptake inhibition due 






Figure 4.1  Microdialysis probe placements within the ventral tegmental area 
Coronal sections showing representative probe placements for Experiment 1 (A) and 
Experiment 2 (B). Lines represent 1 mm active dialysis area. Numbers to the right 















































































































































































































































































































































































































































Figure 4.2  Effect of local uptake inhibition by nipecotic acid in microdialysis perfusate 
on GABA concentration in the VTA 
Local application of 100 and 300 μM nipecotic acid significantly increased GABA 
concentration compared to control rats (* indicates p<0.05, ## indicates p<0.001). Each 
concentration of nipecotic acid (30, 100, 300 μM) was administered in sequential order 
for 60 minutes (n=4). In control rats, manual syringe changes occurred at the same times 
as the nipecotic acid group but syringes only contained artificial cerebrospinal fluid 




































Figure 4.3  Regression lines showing extracellular concentration and extraction fraction 
for samples collected during baseline, during nipecotic acid perfusion and 
return to baseline 
The effect of four GABA concentrations (0, 15, 45, 90 nM) in the perfusate ([GABA]in) 
was tested in four separate groups. The difference between [GABA]in and concentration 
in sample ([GABA]out) was plotted against [GABA]in for the four groups at each time 
interval. Each panel illustrates the data and regression lines for four basal samples (open 
circles, dashed lines) with one regression obtained during or after local nipecotic acid (50 
μM) perfusion (n=24 for combined data). (A) Comparison of the four regressions during 
baseline period. (B) The regression line for the first sample following 20 minutes 
perfusion with nipecotic acid compared to baseline. (C) The regression line for the last 
































































































sample after 100 minutes perfusion with nipecotic acid compared to baseline. (D) The 
regression line for the sample 80 minutes following removal of nipecotic acid in 
perfusate compared to baseline. The r2 values for the basal regressions are ≥ .99. The r2 
values for the time points during and after the nipecotic acid perfusion are .91 – 1.00. 

































Figure 4.4  Time course of extracellular GABA and in vivo extraction fraction during 
local nipecotic acid perfusion in the ventral tegmental area 
Following four baseline samples, the artificial cerebrospinal fluid (ACSF) perfusate was 
changed to include nipecotic acid (50 μM; shaded area) for 100 minutes and then back to 
ACSF for the last four samples. The slopes and x-intercepts of the linear regression lines 
over the course of the experiment are presented. Error bars represent the asymptotic 
standard errors at each time point obtained from regression statistics. Nipecotic acid 
perfusion significantly increased the extracellular concentration of GABA (A) compared 
to baseline samples (## indicates p<0.001 for all samples during 100 – 200 minutes). 
Additionally, nipecotic acid significantly reduced in vivo extraction fraction (B) 
compared to baseline samples (* indicates p<0.05, # p<0.01). The r2 values for the 
individual regressions were .91 – 1.00.  
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Figure 4.5  Time course of the percent baseline change of [GABA]out for the group 
receiving 0 nM GABA and extracellular GABA calculated from quantitative 
microdialysis during local nipecotic acid perfusion in the ventral tegmental 
area 
The percent baseline of x-intercept from the linear regression lines over the course of the 
experiment are presented for extracellular GABA ([GABA]ext; filled circles; n=24). The 
percent baseline of group receiving 0 nM GABA ([0 nM]in; open circles; n=6) in the 
perfusate are presented as mean ± sem. Shaded area indicates local nipecotic acid 




























 The present results provide the first neurochemical evidence that inhibiting GATs 
significantly reduces in vivo extraction fraction using quantitative microdialysis. Delivery 
of nipecotic acid through the microdialysis probe significantly increased extracellular 
VTA GABA while reducing in vivo extraction fraction. The decrease in extraction 
fraction returned to baseline within the first sample following removal of the uptake 
inhibitor. As a result of reduced in vivo extraction fraction, conventional microdialysis 
substantially underestimated the increase in extracellular GABA concentration observed 
following local GAT inhibition. Consistent with measurements for monoamines, these 
results suggest in vivo extraction fraction reflects changes in GABA clearance that may 
influence the interpretation of the effects of drugs on dialysate GABA concentration 
within the VTA.  
 The principle finding of this study is that in vivo extraction fraction is sensitive to 
changes in GABA uptake in the VTA using quantitative microdialysis. Quantitative 
microdialysis has been applied extensively to determine actual extracellular 
concentrations of neurotransmitters during acute or following chronic drug 
administration. Previous studies have shown that extraction fraction, or in vivo recovery 
of the microdialysis probe, represents an indirect measure of clearance for monoamines 
and acetylcholine (Cosford et al. 1996; Parsons et al. 1991; Parsons and Justice 1992; 
Smith and Justice 1994; Vinson and Justice 1997). Changes in dopamine uptake 
measured by in vivo extraction fraction have further been confirmed using voltammetry 
(Chen 2005). To our knowledge, the current results are the first to extend these findings 
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that in vivo extraction fraction measured using microdialysis may also be an estimate of 
GABA clearance.  
 While there are multiple mechanisms present for release and uptake of amino acid 
neurotransmitters such as glutamate and GABA, in support of our findings a previous 
study showed reducing glutamate uptake by local application of an inhibitor through the 
microdialysis probe significantly reduced in vivo extraction fraction in the hippocampus 
(Chefer et al. 2011). However, there are mixed results on whether in vivo extraction 
fraction in quantitative microdialysis studies corresponds to changes in either glutamate 
transporter function or protein expression (Ding et al. 2013; Melendez et al. 2005; Pati et 
al. 2016; Shen et al. 2014).  
 Using quantitative microdialysis under transient conditions, we were able to show 
in vivo extraction fraction was significantly reduced in the first sample following GAT 
inhibition and returned to baseline levels following removal of the drug. These results 
suggest that small changes in GABA uptake can be detected easily using this technique, 
which is advantageous when investigating the mechanism of action of drugs as extraction 
fraction can change over time (Cosford et al. 1994). Additionally, local perfusion through 
the probe in the absence of other drugs or chronic treatments (e.g. cocaine, ethanol) 
eliminates the potential confound of other release mechanisms potentially contributing to 
the observed change in extraction fraction. However, we did not compare our results to 
extraction fraction of the probe in vitro or assess in vivo GAT function in this study so 
future studies are necessary to directly measure whether in vivo extraction fraction can be 
used as a measure of GABA clearance.   
 
 96 
 The activity of GATs to regulate synaptic transmission and prevent neuronal 
spillover is critical to maintain extracellular GABA levels. Consistent with previous 
reports, nipecotic acid perfusion caused a dose-dependent increase in extracellular GABA 
concentration measured with conventional microdialysis (DeGroote and Linthorst 2007; 
Rea et al. 2005; Vihavainen et al. 2008; Westerink and de Vries 1989). Our results from 
the quantitative microdialysis experiment further indicate reduced in vivo extraction 
fraction following GAT inhibition leads to an underestimation in the increase in 
extracellular GABA measured by conventional microdialysis. It is possible a portion of 
the extracellular GABA measured is due to mechanisms other than inhibiting uptake as 
nipecotic acid has previously been reported able to release GABA stores through 
heteroexchange at higher concentrations (Johnston et al. 1976; Solís and Nicoll 1992; 
Szerb 1982). However, only a fraction of the concentration of nipecotic acid used in our 
study crosses the probe membrane therefore possible effects on heteroexchange are likely 
minimal. Nipecotic acid potently inhibits both GAT-1 and GAT-3 on neurons and 
astrocytes (Krogsgaard-Larsen et al. 1987; Madsen et al. 2010). Both GAT-1 and GAT-3 
isoforms are expressed in the VTA, although little is known on the distribution and 
heterogeneity in function that may contribute to the regulation of extracellular GABA in 
this region (Borden 1996; Durkin et al. 1995). The contribution of GAT-1 and GAT-3 to 
maintain extracellular GABA concentration differs between brain regions (Dalby 2000; 
Kersanté et al. 2013), therefore additional studies are needed to determine the role of 
individual GAT isoforms in maintaining extracellular GABA levels in the VTA.  
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 The range of reported basal dialysate GABA concentrations in the VTA measured 
using conventional microdialysis varies significantly (Fliegel et al. 2013). Using 
quantitative microdialysis, the extracellular VTA GABA concentration in our study was 
approximately 45 nM. These results confirm extracellular GABA is maintained in the 
VTA at low concentrations similar to other brain regions (Wlodarczyk et al. 2013; Xi et 
al. 2003). The majority of the probes in the quantitative microdialysis experiment were 
located in the posterior VTA. The posterior VTA was targeted due to its role in the 
rewarding effects of many drugs of abuse (Sanchez-Catalan et al. 2014). However, due to 
the heterogeneity in GABAergic inputs to and local interneurons within the VTA (Oliva 
and Wanat 2016), it is possible the extracellular GABA concentration may differ for 
other subregions. For example, a recent study used low-flow push-pull perfusion to 
measure the extracellular concentration of multiple neurotransmitters with higher spatial 
resolution in the brain (Slaney et al. 2013). These authors determined the GABA 
concentration in the VTA to be 160 ± 50 nM, and noted significant differences between 
their results and extracellular concentrations previously reported for amino acid 
neurotransmitters in other brain regions. It is possible lack of in vivo calibration for the 
push-pull method, probe placement or greater tissue damage from the microdialysis probe 
could contribute to the difference in extracellular concentration compared to our current 
results.  
 Importantly, basal extracellular GABA concentrations are derived from both 
neuronal and non-neuronal sources that do not meet some classical criteria for exocytotic 
release (Del Arco et al. 2003; Timmerman and Westerink 1997; van der Zeyden et al. 
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2008). In addition to the current results using nipecotic acid perfusion, our preliminary 
experiments demonstrated a potassium-evoked increase and a reduction following 
baclofen perfusion on VTA GABA concentrations (data not shown). We did not test the 
sensitivity of extracellular GABA to calcium omission or tetrodotoxin in the current 
experiment, therefore we are unable to determine the portion of extracellular 
concentration derived from neuronal sources. However, a previous study found dialysate 
GABA concentration stimulated by nipecotic acid perfusion was reduced by 
approximately 50% following co-administration with tetrodotoxin (Vihavainen et al. 
2008). In contrast to glutamate transporters, GATs are primarily located on neurons 
(Zhou and Danbolt 2013). These data suggest inhibiting GATs prior to drug 
administration or manipulation may provide a better index for changes in neuronal 
GABA release by measuring synaptic spillover. Based on our current results, the direct 
effects from GAT inhibitors on in vivo extraction fraction underestimates changes in 
dialysate concentration that may be observed following experimental manipulation using 
this technique. Additionally, there may also be effects on GABA clearance mechanisms 
from drug administration itself within the experiment that could influence the in vivo 
extraction fraction and interpretation of microdialysis results.  
 Taken together, the present results are the first to demonstrate inhibiting GABA 
uptake significantly reduces in vivo extraction fraction as measured by quantitative 
microdialysis in the VTA. Our results indicate that in vivo extraction fraction may be a 
critical factor when interpreting microdialysis data examining the mechanism of action of 
drugs on extracellular GABA concentration. Extracellular GABA concentration can alter 
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membrane expression and mobility of GATs influencing the strength of GABAergic 
signaling in the brain (Scimemi 2014). Using quantitative microdialysis, examining in 
vivo extraction fraction changes over time may be a valuable tool to investigate how 
GABA uptake mechanisms are regulated and better define the role of extracellular 
GABA in the VTA in mediating the effects of drugs of abuse or expression of drug-

















Chapter 5: Concluding remarks and future studies 
 
NALTREXONE EFFICACY IN AN ADOLESCENT RAT MODEL 
 The first experiment in this dissertation examined the efficacy of systemic 
naltrexone to reduce operant ethanol self-administration behaviors in an adolescent 
animal model. Our results show that naltrexone significantly reduced operant ethanol 
self-administration and “relapse” seeking of ethanol in rats that began drinking in 
adolescence to a similar degree as rats that began drinking in adulthood. Our findings 
extend current work that has shown naltrexone decreases operant ethanol self-
administration in adult animal models (Ciccocioppo et al. 2003; Gonzales and Weiss 
1998; Hay et al. 2013; Henderson-Redmond and Czachowski 2014). These results also 
provide preclinical evidence to support the initial positive results from clinical use of 
naltrexone in reducing alcohol drinking in adolescent and young adults (Miranda et al. 
2014; O’Malley et al. 2015). 
 We hypothesize that opioid receptor antagonism is the mechanism by which 
naltrexone reduced ethanol self-administration in rats that began operant ethanol self-
administration in adolescence. Limited evidence suggests there are no differences in 
MOR expression in the nucleus accumbens across adolescence in Long Evans rats, 
although the VTA was not examined (Ellgren et al. 2008). Interestingly, beta-endorphin 
levels in the VTA were reduced in adolescent rats with home cage access to ethanol 
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(Palm and Nylander 2014). Therefore, future studies are still required to determine MOR 
expression and function within the VTA during adolescence.  
 Opioid receptor antagonism attenuates ethanol-stimulated dopamine release in the 
nucleus accumbens during ethanol self-administration (Gonzales and Weiss 1998; 
Middaugh et al. 2003). During development, dopamine neuron firing rate in the VTA 
peaks in late adolescence (McCutcheon and Marinelli 2009; McCutcheon et al. 2012). 
While some microdialysis studies have suggested basal extracellular dopamine 
concentration in the nucleus accumbens shows a similar pattern (Badanich et al. 2006; 
Philpot et al. 2009), other studies have reported no differences (Frantz et al. 2007; 
Natividad et al. 2010; Natividad et al. 2012). However, there are currently no 
investigations monitoring dopamine concentration during operant ethanol self-
administration in rats that began drinking in adolescence.  
 The conventional mechanism by which naltrexone is thought to attenuate ethanol-
stimulated dopamine release is due to antagonism of MORs on GABAergic neurons 
within the VTA, or possibly RMTg (Johnson and North 1992; Lecca et al. 2011; Lecca et 
al. 2012). However, dopamine neurons in the VTA possess a different composition of 
opioid receptors dependent on projection target and not all GABAergic interneurons are 
inhibited by MOR agonists (Ford et al. 2006; Margolis et al. 2008; Margolis et al. 2012). 
Previous studies have shown effects on postsynaptic kappa opioid receptors can be 
separated by projection target for VTA dopamine neurons (Ford et al. 2006; Margolis et 
al. 2006a; Margolis et al. 2008). Therefore, the effects of MORs on dopamine and GABA 
neurons may also sort by projection target. To our knowledge, there are no studies 
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investigating whether the effects of nonselective opioid antagonism are also 
heterogeneous within the VTA.  However, it is likely that systemic naltrexone 
administration produces cell-specific effects in the VTA that would then lead to 
differential alteration of neuronal circuits that depend on the projection target from the 
VTA. Future work is still needed to determine which neuronal circuits contribute to the 
reduction in ethanol consumption observed following naltrexone administration. 
 One potential mechanism underlying effects of opioid receptor blockade on 
ethanol-stimulated dopamine release following chronic ethanol consumption is an 
increase in extracellular GABA concentration in the VTA. MOR knockout mice display 
significantly higher dialysate GABA concentration, suggesting opioid tone is present 
within the VTA under basal conditions (Chefer et al. 2009a). Additionally, opioid peptide 
levels in the VTA were reduced following chronic ethanol consumption (Palm and 
Nylander 2014). Recently, nonoperant ethanol self-administration in adolescence was 
shown to increase GABAergic transmission onto VTA dopamine neurons in adulthood 
(Schindler et al. 2016).  Our current results show naltrexone significantly reduced ethanol 
intake in both age groups, however rats that began operant self-administration in 
adolescence displayed less “relapse” to ethanol seeking behavior in adulthood. Therefore, 
future studies should examine whether age-related initiation of ethanol consumption 
contributes to differences in neurochemical responses to ethanol or naltrexone during 
operant self-administration. These experiments may provide further insight into 




 It is important to emphasize that most animal experiments including the current 
results show naltrexone reduces ethanol consumption following acute administration. 
However, naltrexone is most often used clinically to reduce alcohol drinking as a chronic 
treatment. While no differences were found in extracellular naltrexone concentration 
between acute or chronic treatment over 10 days (Burattini et al. 2008), chronic 
naltrexone treatment has been shown to upregulate MOR receptors throughout the brain, 
including in the VTA (Lesscher et al. 2003). Indeed, some studies have shown that 
repeated or chronic administration of naltrexone can result in tolerance in the ability to 
reduce ethanol consumption in animal models (Boyle et al. 1998; Myers et al. 1986; 
Sable et al. 2006; Stromberg et al. 1998). Interestingly, adolescent rats were reported to 
be less tolerant to repeated dosing of naltrexone compared to adult rats in a 2-bottle 
choice ethanol paradigm (Sable et al. 2006). Therefore, future studies are necessary to 
examine chronic naltrexone dosing on MOR receptor regulation and operant ethanol self-
administration during adolescence. 
 In our study, adolescent rats began operant ethanol self-administration at P36, 
which corresponds to early adolescence before the onset of puberty in male rats (Lewis et 
al. 2002; McCutcheon and Marinelli 2009; Spear 2000). This age was chosen to model 
epidemiological data reporting individuals that began drinking alcohol before the age of 
14 were four times more likely to develop future alcohol dependence (DeWit et al. 2000; 
Grant and Dawson 1997). However, the firing rate of VTA dopamine neurons before 
pubertal onset is lower than in late adolescence around P45, when firing rate peaks 
(McCutcheon and Marinelli 2009). Adolescents are generally characterized to be more 
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sensitive to the rewarding properties and less sensitive to aversive properties of drugs of 
abuse including ethanol (Doremus-Fitzwater and Spear 2016). Therefore, it is possible 
the rewarding and aversive properties of ethanol may differ between the age of onset used 
in our study compared to if operant ethanol self-administration began during mid to late 
adolescence.  
 
REGULATION OF EXTRACELLULAR GABA IN THE VTA 
 Our results are the first to report extracellular GABA concentration in the VTA 
measured using quantitative microdialysis. Functional differences in GABAergic 
transmission (Ikemoto 2007; Sanchez-Catalan et al. 2014) and ethanol reinforcement 
(Rodd-Henricks et al. 2000) are reported between VTA subregions. The basal 
extracellular GABA concentration in the current study (~45 nM) is largely represented by 
microdialysis probes located within the pVTA. Local microinjection of picrotoxin into 
the aVTA, but not the pVTA, increased dialysate dopamine concentration in the nucleus 
accumbens (Ding et al. 2009). These results suggest there may be increased GABAergic 
tone present in the aVTA. Therefore, we speculate heterogeneity in extracellular GABA 
concentration may also exist within the VTA, which could be dependent on GABAergic 
inputs and/or differences in GAT distribution. Future research should aim to determine 
the relative contribution of inhibitory inputs and GAT subtypes to extracellular GABA 
concentration following selective inactivation.   
 The efficiency of GATs is hypothesized to prevent changes in neuronal release of 
GABA from being detected by microdialysis in the extracellular space, which has 
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potential implications for interpreting whether drugs of abuse cause changes in 
extracellular GABA concentration. Indeed, our results further confirm extracellular 
GABA concentration in the VTA is highly regulated by GATs. Previous studies found 
local morphine delivered through the microdialysis probe caused a reduction in dialysate 
GABA concentration in the VTA (Klitenick et al. 1992; Sotomayor et al. 2005), but no 
effects were initially observed following systemic morphine administration (Ojanen et al. 
2007). However, when GATs were inhibited using nipecotic acid, the increase in 
dialysate GABA concentration following nipecotic acid perfusion was reduced in animals 
that received an intravenous infusion of morphine (Vihavainen et al. 2008). Contrasting 
reports using ex vivo electrophysiological approaches show acute ethanol either increases 
(Theile et al. 2008; Theile et al. 2009; Theile et al. 2011) or decreases (Xiao et al. 2007; 
Xiao and Ye 2008) GABA release in the VTA, although the effect may also depend on 
subregion (Guan et al. 2012). In contrast, no changes in extracellular GABA measured by 
microdialysis have been observed following acute ethanol administration (Cowen et al. 
1998; Kemppainen et al. 2010; Ojanen et al. 2007; Yan et al. 2005). Our current results 
suggest inhibiting GABA uptake prior to ethanol administration could be a useful 
strategy to determine whether acute ethanol results in changes to extracellular GABA 
concentration, which has potential to clarify the controversy between electrophysiological 
data using an in vivo model.   
 In contrast to acute ethanol administration, the effects of chronic ethanol 
consumption on extracellular GABA in the VTA are unexplored. Chronic ethanol has 
been shown to increase GABA neuron firing in the VTA (Gallegos et al. 1999) and basal 
 
 106 
extracellular dopamine concentration in the pVTA was lower in rats following chronic 
ethanol consumption measured using quantitative microdialysis (Engleman et al. 2011). 
Chronic ethanol injections caused an elevation in basal dialysate GABA concentration in 
the nucleus accumbens (Dahchour et al. 1996), but no changes were detected during an 
acute ethanol challenge (Dahchour et al. 1994). Furthermore, higher levels of GAT-1 and 
GAT-3 were observed in the hippocampus of rats dependent on a liquid ethanol diet, 
although the VTA was not examined (Devaud 2001). Therefore, while GAT activity may 
prevent detection of acute changes in extracellular GABA, it is possible alterations in the 
regulation of basal extracellular GABA are implicated following chronic ethanol 
exposure. 
 Future experiments should also investigate whether GATs in the VTA may have a 
direct role in the maintenance of drug-dependent behaviors. Recently, GAT-1 was shown 
to enhance GABA release during opioid withdrawal in the periaqueductal gray (Bagley et 
al. 2011). GATs are also present on midbrain dopamine neurons to facilitate co-release of 
GABA (Tritsch et al. 2014). Interestingly, there is also clinical evidence showing 
tiagabine, a GAT-1 selective inhibitor, reduced alcohol withdrawal signs to a similar 
degree as benzodiazepines (Myrick et al. 2005). More studies are necessary to determine 
whether in vivo extraction fraction can be used as an accurate index of GABA clearance. 
However, quantitative microdialysis may prove to be a useful technique to examine 
functional changes in GAT activity during acute or chronic drug exposure. 
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Together, the results of the current experiments provide the foundation to further 
investigate the interaction between ethanol, the opioid peptide system and extracellular 
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